<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

<meta charset="utf-8">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />
<meta name="author" content="Tim Woelfle" />

<meta name="date" content="2024-04-21" />


<title>PRISMA &amp; AMSTAR in Cullis 2017: LLMs combined (consistent in 5/9 assessments) vs Human Consensus</title>

<meta property="og:title" content="PRISMA &amp; AMSTAR in Cullis 2017: LLMs combined (consistent in 5/9 assessments) vs Human Consensus" />

<meta name='viewport' content='width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no' />

<link rel="icon" href="data:image/x-icon;" type="image/x-icon">


<script type="text/javascript">
window.FlexDashboardComponents = [];
</script>

<script id="flexdashboard-navbar" type="application/json">
[{"title":"Home","href":"../index.html"},{"title":"Source Code","icon":"fa-github","href":"https://github.com/timwoelfle/Research-Assessment-AI/","align":"right"}]
</script>
<script src="lib/header-attrs-2.21/header-attrs.js"></script>
<script src="lib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="lib/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="lib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="lib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="lib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="lib/stickytableheaders-0.1.19/jquery.stickytableheaders.min.js"></script>
<link href="lib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="lib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<link href="lib/value-box-accent-static-0.6.1/theme-cosmo-value-box.css" rel="stylesheet" />
<link href="lib/flexdashboard-css-0.6.1/flexdashboard.min.css" rel="stylesheet" />
<link href="lib/flexdashboard-css-0.6.1/theme-cosmo.css" rel="stylesheet" />
<script src="lib/htmlwidgets-1.6.2/htmlwidgets.js"></script>
<link href="lib/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="lib/datatables-binding-0.28/datatables.js"></script>
<link href="lib/dt-core-1.13.4/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="lib/dt-core-1.13.4/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="lib/dt-core-1.13.4/js/jquery.dataTables.min.js"></script>
<link href="lib/crosstalk-1.2.0/css/crosstalk.min.css" rel="stylesheet" />
<script src="lib/crosstalk-1.2.0/js/crosstalk.min.js"></script>
<style type="text/css">
/*
  CSS for flexdashboard.js' use of Sly(). The sizing/position of this CSS needs to be
  applied _before_ flexdashboard.js initializes, which is why this CSS has been pulled
  out from flexdashboard.scss and inlined in the document's head.
*/

.storyboard-nav button {
  background: transparent;
  border: 0;
  opacity: .3;
  outline: none;
  padding: 0;
}

.storyboard-nav button:hover,
.storyboard-nav button:hover {
  opacity: .5;
}

.storyboard-nav button:disabled,
.storyboard-nav button:disabled {
  opacity: .1;
}

.storyboard-nav .sbnext,
.storyboard-nav .sbprev {
  float: left;
  width: 2%;
  height: 120px;
}

.storyboard-nav .sbprev {
  text-align: left;
  width: 2%;
}

.storyboard-nav .sbnext {
  float: right;
  text-align: right;
  margin-right: 8px;
}

.storyboard-nav .sbframelist {
  margin: 0 auto;
  width: 94%;
  height: 120px;
  overflow: hidden;
  text-shadow: none;
  margin-bottom: 8px;
}

.storyboard-nav .sbframelist ul {
  list-style: none;
  margin: 0;
  padding: 0;
  height: 100%;
}

.storyboard-nav .sbframelist ul li {
  float: left;
  width: 270px;
  height: 100%;
  padding: 10px 10px 10px 10px;
  margin-right: 8px;
  text-align: left;
  cursor: pointer;
}

.storyboard-nav .sbframelist ul li:last-child {
  margin-right: 0px;
}

.sbframe-commentary {
  width: 300px;
}

.sbframe-commentary ul {
  padding-left: 22px;
}

.sbframe.active {
  display: flex;
}

.sbframe:not(.active) {
  display: none;
}
@media only screen and (min-width: 768px) {
html, body {
  height: 100%;
}

#dashboard-container {
  height: 100%;
}
}
</style>



</head>

<body>

<div class="navbar navbar-inverse navbar-fixed-top" role="navigation">
<div class="container-fluid">
<div class="navbar-header">

<span class="navbar-logo pull-left">
  
</span>
<span class="navbar-brand">
  PRISMA &amp; AMSTAR in Cullis 2017: LLMs combined (consistent in 5/9 assessments) vs Human Consensus
  <span class="navbar-author">
    Tim Woelfle &mdash; 2024-04-21
    </span>
</span>

<button id="navbar-button" type="button" class="navbar-toggle collapsed pull-right" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</button>

</div>
<div id="navbar" class="navbar-collapse collapse">
<ul class="nav navbar-nav navbar-left">
</ul>
<ul class="nav navbar-nav navbar-right">
</ul>
</div><!--/.nav-collapse-->
</div><!--/.container-->
</div><!--/.navbar-->

<script type="text/javascript">


var FlexDashboard = (function () {

  // initialize options
  var _options = {};

  var FlexDashboard = function() {

    // default options
    _options = $.extend(_options, {
      theme: "cosmo",
      fillPage: false,
      orientation: 'columns',
      storyboard: false,
      defaultFigWidth: 576,
      defaultFigHeight: 461,
      defaultFigWidthMobile: 360,
      defaultFigHeightMobile: 461,
      isMobile: false,
      isPortrait: false,
      resize_reload: true
    });
  };

  function init(options) {

    // extend default options
    $.extend(true, _options, options);

    // add ids to sections that don't have them (pandoc won't assign ids
    // to e.g. sections with titles consisting of only chinese characters)
    var nextId = 1;
    $('.level1:not([id]),.level2:not([id]),.level3:not([id])').each(function() {
      $(this).attr('id', 'dashboard-' + nextId++);
    });

    // find navbar items
    var navbarItems = $('#flexdashboard-navbar');
    if (navbarItems.length)
      navbarItems = JSON.parse(navbarItems.html());
    addNavbarItems(navbarItems);

    // find the main dashboard container
    var dashboardContainer = $('#dashboard-container');

    // resolve mobile classes
    resolveMobileClasses(dashboardContainer);

    // one time global initialization for components
    componentsInit(dashboardContainer);

    // look for a global sidebar
    var globalSidebar = dashboardContainer.find(".section.level1.sidebar");
    if (globalSidebar.length > 0) {

      // global layout for fullscreen displays
      if (!isMobilePhone()) {

         // hoist it up to the top level
         globalSidebar.insertBefore(dashboardContainer);

         // lay it out (set width/positions)
         layoutSidebar(globalSidebar, dashboardContainer);

      // tuck sidebar into first page for mobile phones
      } else {

        // convert it into a level3 section
        globalSidebar.removeClass('sidebar');
        globalSidebar.removeClass('level1');
        globalSidebar.addClass('level3');
        var h1 = globalSidebar.children('h1');
        var h3 = $('<h3></h3>');
        h3.append(h1.contents());
        h3.insertBefore(h1);
        h1.detach();

        // move it into the first page
        var page = dashboardContainer.find('.section.level1').first();
        if (page.length > 0)
          page.prepend(globalSidebar);
      }
    }

    // look for pages to layout
    var pages = $('div.section.level1');
    if (pages.length > 0) {

        // find the navbar and collapse on clicked
        var navbar = $('#navbar');
        navbar.on("click", "a[data-toggle!=dropdown]", null, function () {
           navbar.collapse('hide');
        });

        // envelop the dashboard container in a tab content div
        dashboardContainer.wrapInner('<div class="tab-content"></div>');

        pages.each(function(index) {

          // lay it out
          layoutDashboardPage($(this));

          // add it to the navbar
          addToNavbar($(this), index === 0);

        });

    } else {

      // remove the navbar and navbar button if we don't
      // have any navbuttons
      if (navbarItems.length === 0) {
        $('#navbar').remove();
        $('#navbar-button').remove();
      }

      // add the storyboard class if requested
      if (_options.storyboard)
        dashboardContainer.addClass('storyboard');

      // layout the entire page
      layoutDashboardPage(dashboardContainer);
    }

    // if we are in shiny we need to trigger a window resize event to
    // force correct layout of shiny-bound-output elements
    if (isShinyDoc())
      $(window).trigger('resize');

    // make main components visible
    $('.section.sidebar').css('visibility', 'visible');
    dashboardContainer.css('visibility', 'visible');

    // handle location hash
    handleLocationHash();

    // intialize prism highlighting
    initPrismHighlighting();

    // record mobile and orientation state then register a handler
    // to refresh if resize_reload is set to true and it changes
    _options.isMobile = isMobilePhone();
    _options.isPortrait = isPortrait();
    if (_options.resize_reload) {
      $(window).on('resize', function() {
        if (_options.isMobile !== isMobilePhone() ||
            _options.isPortrait !== isPortrait()) {
          window.location.reload();
        }
      });
    } else {
      // if in desktop mode and resizing to mobile, make sure the heights are 100%
      // This enforces what `fillpage.css` does for "wider" pages.
      // Since we are not reloading once the page becomes small, we need to force the height to 100%
      // This is a new situation introduced when `_options.resize_reload` is `false`
      if (! _options.isMobile) {
        // only add if `fillpage.css` was added in the first place
        if (_options.fillPage) {
          // fillpage.css
          $("html,body,#dashboard").css("height", "100%");
        }
      }
    }
    // trigger layoutcomplete event
    dashboardContainer.trigger('flexdashboard:layoutcomplete');
  }

  function resolveMobileClasses(dashboardContainer) {
     // add top level layout class
    dashboardContainer.addClass(isMobilePhone() ? 'mobile-layout' :
                                                  'desktop-layout');

    // look for .mobile sections and add .no-mobile to their peers
    var mobileSections = $('.section.mobile');
    mobileSections.each(function() {
       var id = $(this).attr('id');
       var nomobileId = id.replace(/-\d+$/, '');
       $('#' + nomobileId).addClass('no-mobile');
    });
  }

  function addNavbarItems(navbarItems) {

    var navbarLeft = $('ul.navbar-left');
    var navbarRight = $('ul.navbar-right');

    for (var i = 0; i<navbarItems.length; i++) {

      // get the item
      var item = navbarItems[i];

      // determine the container
      var container = null;
      if (item.align === "left")
        container = navbarLeft;
      else
        container = navbarRight;

      // navbar menu if we have multiple items
      if (item.items) {
        var menu = navbarMenu(null, item.icon, item.title, container);
        for (var j = 0; j<item.items.length; j++) {
          var subItem = item.items[j];
          var li = $('<li></li>');
          var a = navbarLink(subItem.icon, subItem.title, subItem.href, subItem.target);
          a.removeClass("nav-link").addClass("dropdown-item");
          li.append(a);
          menu.append(li);
        }
      } else {
        var li = $('<li class="nav-item"></li>');
        li.append(navbarLink(item.icon, item.title, item.href, item.target));
        container.append(li);
      }
    }
  }

  // create or get a reference to an existing dropdown menu
  function navbarMenu(id, icon, title, container) {
    var existingMenu = [];
    if (id)
      existingMenu = container.children('#' + id);
    if (existingMenu.length > 0) {
      return existingMenu.children('ul');
    } else {
      var li = $('<li class="nav-item"></li>');
      if (id)
        li.attr('id', id);
      li.addClass('dropdown');
      // auto add "Share" title on mobile if necessary
      if (!title && icon && (icon === "fa-share-alt") && isMobilePhone())
        title = "Share";
      if (title) {
        title = title + ' <span class="caret"></span>';
      }
      var a = navbarLink(icon, title, "#");
      a.addClass('dropdown-toggle');
      a.attr('data-toggle', 'dropdown');
      a.attr('data-bs-toggle', 'dropdown');
      a.attr('role', 'button');
      a.attr('aria-expanded', 'false');
      li.append(a);
      var ul = $('<ul class="dropdown-menu"></ul>');
      ul.attr('role', 'menu');
      li.append(ul);
      container.append(li);
      return ul;
    }
  }

  function addToNavbar(page, active) {

    // capture the id and data-icon attribute (if any)
    var id = page.attr('id');
    var icon = page.attr('data-icon');
    var navmenu = page.attr('data-navmenu');

    // get hidden state (transfer this to navbar)
    var hidden = page.hasClass('hidden');
    page.removeClass('hidden');

    // sanitize the id for use with bootstrap tabs
    id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
    page.attr('id', id);

    // get the wrapper
    var wrapper = page.closest('.dashboard-page-wrapper');

    // move the id to the wrapper
    page.removeAttr('id');
    wrapper.attr('id', id);

    // add the tab-pane class to the wrapper
    wrapper.addClass('tab-pane');
    if (active)
      wrapper.addClass('active');

    // get a reference to the h1, discover its inner contens, then detach it
    var h1 = wrapper.find('h1').first();
    var title = h1.contents();
    h1.detach();

    // create a navbar item
    var li = $('<li></li>');
    var a = navbarLink(icon, title, '#' + id);
    a.attr('data-toggle', 'tab');
    li.append(a);

    // add it to the navbar (or navbar menu if specified)
    var container = $('ul.navbar-left');
    if (navmenu) {
      var menuId = navmenu.replace(/\s+/g, '');
      var menu = navbarMenu(menuId, null, navmenu, container);
      li.find("> a").removeClass("nav-link").addClass("dropdown-item");
      menu.append(li);
    } else {
      li.addClass("nav-item")
      container.append(li);
    }

    // hide it if requested
    if (hidden)
      li.addClass('hidden');
  }

  function navbarLink(icon, title, href, target) {

    var a = $('<a class="nav-link"></a>');
    if (icon) {

      // get the name of the icon set and icon
      var dashPos = icon.indexOf("-");
      var iconSet = null;
      var iconSplit = icon.split(" ");
      if (iconSplit.length > 1) {
        iconSet = iconSplit[0];
        icon = iconSplit.slice(1).join(" ");
      } else {
        iconSet = icon.substring(0, dashPos);
      }
      var iconName = icon.substring(dashPos + 1);

      // create the icon
      var iconElement = $('<span class="' + iconSet + ' ' + icon + '"></span>');
      if (title)
        iconElement.css('margin-right', '7px');
      a.append(iconElement);
      // if href is null see if we can auto-generate based on icon (e.g. social)
      if (!href)
        maybeGenerateLinkFromIcon(iconName, a);
    }
    if (title)
      a.append(title);

    // add the href.
    if (href) {
      if (href === "source_embed") {
        a.attr('href', '#');
        a.attr('data-featherlight', "#flexdashboard-source-code");
        a.featherlight({
            beforeOpen: function(event){
              $('body').addClass('unselectable');
            },
            afterClose: function(event){
              $('body').removeClass('unselectable');
            }
        });
      } else {
        a.attr('href', href);
      }
    }

    // add the arget
    if (target)
      a.attr('target', target);

    return a;
  }

  // auto generate a link from an icon name (e.g. twitter) when possible
  function maybeGenerateLinkFromIcon(iconName, a) {

     var serviceLinks = {
      "twitter": "https://twitter.com/share?text=" + encodeURIComponent(document.title) + "&url="+encodeURIComponent(location.href),
      "facebook": "https://www.facebook.com/sharer/sharer.php?s=100&p[url]="+encodeURIComponent(location.href),
      "linkedin": "https://www.linkedin.com/shareArticle?mini=true&url="+encodeURIComponent(location.href) + "&title=" + encodeURIComponent(document.title),
      "pinterest": "https://pinterest.com/pin/create/link/?url="+encodeURIComponent(location.href) + "&description=" + encodeURIComponent(document.title)
    };

    var makeSocialLink = function(a, href) {
      a.attr('href', '#');
      a.on('click', function(e) {
        e.preventDefault();
        window.open(href);
      });
    };

    $.each(serviceLinks, function(key, value) {
      if (iconName.indexOf(key) !== -1)
        makeSocialLink(a, value);
    });
  }

  // layout a dashboard page
  function layoutDashboardPage(page) {

    // use a page wrapper so that free form content above the
    // dashboard appears at the top rather than the side (as it
    // would without the wrapper in a column orientation)
    var wrapper = $('<div class="dashboard-page-wrapper"></div>');
    page.wrap(wrapper);

    // if there are no level2 or level3 headers synthesize a level3
    // header to contain the (e.g. frame it, scroll container, etc.)
    var headers = page.find('h2,h3');
    if (headers.length === 0)
      page.wrapInner('<div class="section level3"></div>');

    // hoist up any content before level 2 or level 3 headers
    var children = page.children();
    children.each(function(index) {
      if ($(this).hasClass('level2') || $(this).hasClass('level3'))
        return false;
      $(this).insertBefore(page);
    });

    // determine orientation and fillPage behavior for distinct media
    var orientation, fillPage, storyboard;

    // media: mobile phone
    if (isMobilePhone()) {

      // if there is a sidebar we need to ensure it's content
      // is properly framed as an h3
      var sidebar = page.find('.section.sidebar');
      sidebar.removeClass('sidebar');
      sidebar.wrapInner('<div class="section level3"></div>');
      var h2 = sidebar.find('h2');
      var h3 = $('<h3></h3>');
      h3.append(h2.contents());
      h3.insertBefore(h2);
      h2.detach();

      // wipeout h2 elements then enclose them in a single h2
      var level2 = page.find('div.section.level2');
      level2.each(function() {
        level2.children('h2').remove();
        level2.children().unwrap();
      });
      page.wrapInner('<div class="section level2"></div>');

      // substitute mobile images
      if (isPortrait()) {
        var mobileFigures = $('img.mobile-figure');
        mobileFigures.each(function() {
          // get the src (might be base64 encoded)
          var src = $(this).attr('src');

          // find it's peer
          var id = $(this).attr('data-mobile-figure-id');
          var img = $('img[data-figure-id=' + id + "]");
          img.attr('src', src)
             .attr('width', _options.defaultFigWidthMobile)
             .attr('height', _options.defaultFigHeightMobile);
        });
      }

      // hoist storyboard commentary into it's own section
      if (page.hasClass('storyboard')) {
        var commentaryHR = page.find('div.section.level3 hr');
        commentaryHR.each(function() {
          var commentary = $(this).nextAll().detach();
          var commentarySection = $('<div class="section level3"></div>');
          commentarySection.append(commentary);
          commentarySection.insertAfter($(this).closest('div.section.level3'));
          $(this).remove();
        });
      }

      // force a non full screen layout by columns
      orientation = _options.orientation = 'columns';
      fillPage = _options.fillPage = false;
      storyboard = _options.storyboard = false;

    // media: desktop
    } else {

      // determine orientation
      orientation = page.attr('data-orientation');
      if (orientation !== 'rows' && orientation != 'columns')
        orientation = _options.orientation;

      // determine storyboard mode
      storyboard = page.hasClass('storyboard');

      // fillPage based on options (force for storyboard)
      fillPage = _options.fillPage || storyboard;

      // handle sidebar
      var sidebar = page.find('.section.level2.sidebar');
      if (sidebar.length > 0)
        layoutSidebar(sidebar, page);
    }

    // give it and it's parent divs height: 100% if we are in fillPage mode
    if (fillPage) {
      page.addClass('vertical-layout-fill');
      page.css('height', '100%');
      page.parents('div').css('height', '100%');
    } else {
      page.addClass('vertical-layout-scroll');
    }

    // perform the layout
    if (storyboard)
      layoutPageAsStoryboard(page);
    else if (orientation === 'rows')
      layoutPageByRows(page, fillPage);
    else if (orientation === 'columns')
      layoutPageByColumns(page, fillPage);
  }

  function layoutSidebar(sidebar, content) {

    // get it out of the header hierarchy
    sidebar = sidebar.first();
    if (sidebar.hasClass('level1')) {
      sidebar.removeClass('level1');
      sidebar.children('h1').remove();
    } else if (sidebar.hasClass('level2')) {
      sidebar.removeClass('level2');
      sidebar.children('h2').remove();
    }

    // determine width
    var sidebarWidth = isTablet() ? 220 : 250;
    var dataWidth = parseInt(sidebar.attr('data-width'));
    if (dataWidth)
      sidebarWidth = dataWidth;

    // set the width and shift the page right to accomodate the sidebar
    sidebar.css('width', sidebarWidth + 'px');
    content.css('padding-left', sidebarWidth + 'px');

    // wrap it's contents in a form
    sidebar.wrapInner($('<form></form>'));
  }

  function layoutPageAsStoryboard(page) {

    // create storyboard navigation
    var nav = $('<div class="storyboard-nav"></div>');

    // add navigation buttons
    var prev = $('<button class="sbprev"><i class="fa fa-angle-left"></i></button>');
    nav.append(prev);
    var next= $('<button class="sbnext"><i class="fa fa-angle-right"></i></button>');
    nav.append(next);

    // add navigation frame
    var frameList = $('<div class="sbframelist"></div>');
    nav.append(frameList);
    var ul = $('<ul></ul>');
    frameList.append(ul);

     // find all the level3 sections (those are the storyboard frames)
    var frames = page.find('div.section.level3');
    frames.each(function() {

      // mark it
      $(this).addClass('sbframe');

      // divide it into chart content and (optional) commentary
      $(this).addClass('dashboard-column-orientation');

      // stuff the chart into it's own div w/ flex
      $(this).wrapInner('<div class="sbframe-component"></div>');
      setFlex($(this), 1);
      var frame = $(this).children('.sbframe-component');

      // extract the title from the h3
      var li = $('<li></li>');
      var h3 = frame.children('h3');
      li.append(h3.contents());
      h3.detach();
      ul.append(li);

      // extract commentary
      var hr = frame.children('hr');
      if (hr.length) {
        var commentary = hr.nextAll().detach();
        hr.remove();
        var commentaryFrame = $('<div class="sbframe-commentary"></div>');
        commentaryFrame.addClass('flowing-content-shim');
        commentaryFrame.addClass('flowing-content-container');
        commentaryFrame.append(commentary);
        $(this).append(commentaryFrame);

        // look for a data-commentary-width attribute
        var commentaryWidth = $(this).attr('data-commentary-width');
        if (commentaryWidth)
          commentaryFrame.css('width', commentaryWidth + 'px');
      }

      // layout the chart (force flex)
      var result = layoutChart(frame, true);

      // ice the notes if there are none
      if (!result.notes)
        frame.find('.chart-notes').remove();

      // set flex on chart
      setFlex(frame, 1);
    });

    // create a div to hold all the frames
    var frameContent = $('<div class="sbframe-content"></div>');
    frameContent.addClass('dashboard-row-orientation');
    frameContent.append(frames.detach());

    // row orientation to stack nav and frame content
    page.addClass('dashboard-row-orientation');
    page.append(nav);
    page.append(frameContent);
    setFlex(frameContent, 1);

    // initialize sly
    var sly = new Sly(frameList, {
    		horizontal: true,
    		itemNav: 'basic',
    		smart: true,
    		activateOn: 'click',
    		startAt: 0,
    		scrollBy: 1,
    		activatePageOn: 'click',
    		speed: 200,
    		moveBy: 600,
    		dragHandle: true,
    		dynamicHandle: true,
    		clickBar: true,
    		keyboardNavBy: 'items',
    		next: next,
    		prev: prev
    	}).init();

    // make first frame active
    frames.removeClass('active');
    frames.first().addClass('active');

    // subscribe to frame changed events
    sly.on('active', function (eventName, itemIndex) {
      frames.removeClass('active');
      frames.eq(itemIndex).addClass('active')
                          .trigger('shown');
    });
  }

  function layoutPageByRows(page, fillPage) {

    // row orientation
    page.addClass('dashboard-row-orientation');

    // find all the level2 sections (those are the rows)
    var rows = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (rows.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      rows = page.find('div.section.level2');
    }

    rows.each(function () {

      // flags
      var haveNotes = false;
      var haveFlexHeight = true;

      // remove the h2
      $(this).children('h2').remove();

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // give it row layout semantics if it's not a tabset
      if (!isTabset)
        $(this).addClass('dashboard-row');

      // find all of the level 3 subheads
      var columns = $(this).find('div.section.level3');

      // determine figureSizes sizes
      var figureSizes = chartFigureSizes(columns);

      // fixup the columns
      columns.each(function(index) {

        // layout the chart (force flex if we are in a tabset)
        var result = layoutChart($(this), isTabset);

        // update flexHeight state
        if (!result.flex)
          haveFlexHeight = false;

        // update state
        if (result.notes)
          haveNotes = true;

        // set the column flex based on the figure width
        // (value boxes will just get the default figure width)
        var chartWidth = figureSizes[index].width;
        setFlex($(this), chartWidth + ' ' + chartWidth + ' 0px');

      });

      // remove empty chart note divs
      if (isTabset)
        $(this).find('.chart-notes').filter(function() {
            return $(this).html() === "&nbsp;";
        }).remove();
      if (!haveNotes)
        $(this).find('.chart-notes').remove();

       // make it a flexbox row
      if (haveFlexHeight)
        $(this).addClass('dashboard-row-flex');

      // now we can set the height on all the wrappers (based on maximum
      // figure height + room for title and notes, or data-height on the
      // container if specified). However, don't do this if there is
      // no flex on any of the constituent columns
      var flexHeight = null;
      var dataHeight = parseInt($(this).attr('data-height'));
      if (dataHeight)
        flexHeight = adjustedHeight(dataHeight, columns.first());
      else if (haveFlexHeight)
        flexHeight = maxChartHeight(figureSizes, columns);
      if (flexHeight) {
        if (fillPage)
          setFlex($(this), flexHeight + ' ' + flexHeight + ' 0px');
        else {
          $(this).css('height', flexHeight + 'px');
          setFlex($(this), '0 0 ' + flexHeight + 'px');
        }
      }

    });
  }

  function layoutPageByColumns(page, fillPage) {

    // column orientation
    page.addClass('dashboard-column-orientation');

    // find all the level2 sections (those are the columns)
    var columns = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (columns.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      columns = page.find('div.section.level2');
    }

    // layout each column
    columns.each(function (index) {

      // remove the h2
      $(this).children('h2').remove();

      // make it a flexbox column
      $(this).addClass('dashboard-column');

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // find all the h3 elements
      var rows = $(this).find('div.section.level3');

      // get the figure sizes for the rows
      var figureSizes = chartFigureSizes(rows);

      // column flex is the max row width (or data-width if specified)
      var flexWidth;
      var dataWidth = parseInt($(this).attr('data-width'));
      if (dataWidth)
        flexWidth = dataWidth;
      else
        flexWidth = maxChartWidth(figureSizes);
      setFlex($(this), flexWidth + ' ' + flexWidth + ' 0px');

      // layout each chart
      rows.each(function(index) {

        // perform the layout
        var result = layoutChart($(this), false);

        // ice the notes if there are none
        if (!result.notes)
          $(this).find('.chart-notes').remove();

        // set flex height based on figHeight, then adjust
        if (result.flex) {
          var chartHeight = figureSizes[index].height;
          chartHeight = adjustedHeight(chartHeight, $(this));
          if (fillPage)
            setFlex($(this), chartHeight + ' ' + chartHeight + ' 0px');
          else {
            $(this).css('height', chartHeight + 'px');
            setFlex($(this), chartHeight + ' ' + chartHeight + ' ' + chartHeight + 'px');
          }
        }
      });
    });
  }

  function chartFigureSizes(charts) {

    // sizes
    var figureSizes = new Array(charts.length);

    // check each chart
    charts.each(function(index) {

      // start with default
      figureSizes[index] = {
        width: _options.defaultFigWidth,
        height: _options.defaultFigHeight
      };

      // look for data-height or data-width then knit options
      var dataWidth = parseInt($(this).attr('data-width'));
      var dataHeight = parseInt($(this).attr('data-height'));
      var knitrOptions = $(this).find('.knitr-options:first');
      var knitrWidth, knitrHeight;
      if (knitrOptions) {
        knitrWidth = parseInt(knitrOptions.attr('data-fig-width'));
        knitrHeight =  parseInt(knitrOptions.attr('data-fig-height'));
      }

      // width
      if (dataWidth)
        figureSizes[index].width = dataWidth;
      else if (knitrWidth)
        figureSizes[index].width = knitrWidth;

      // height
      if (dataHeight)
        figureSizes[index].height = dataHeight;
      else if (knitrHeight)
        figureSizes[index].height = knitrHeight;
    });

    // return sizes
    return figureSizes;
  }

  function maxChartHeight(figureSizes, charts) {

    // first compute the maximum height
    var maxHeight = _options.defaultFigHeight;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].height > maxHeight)
        maxHeight = figureSizes[i].height;

    // now add offests for chart title and chart notes
    if (charts.length)
      maxHeight = adjustedHeight(maxHeight, charts.first());

    return maxHeight;
  }

  function adjustedHeight(height, chart) {
    if (chart.length > 0) {
      var chartTitle = chart.find('.chart-title');
      if (chartTitle.length)
        height += chartTitle.first().outerHeight();
      var chartNotes = chart.find('.chart-notes');
      if (chartNotes.length)
        height += chartNotes.first().outerHeight();
    }
    return height;
  }

  function maxChartWidth(figureSizes) {
    var maxWidth = _options.defaultFigWidth;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].width > maxWidth)
        maxWidth = figureSizes[i].width;
    return maxWidth;
  }

  // layout a chart
  function layoutChart(chart, forceFlex) {

    // state to return
    var result = {
      notes: false,
      flex: false
    };

    // extract the title
    var title = extractTitle(chart);

    // find components that apply to this container
    var components = componentsFind(chart);

    // if it's a custom component then call it and return
    var customComponents = componentsCustom(components);
    if (customComponents.length) {
      componentsLayout(customComponents, title, chart);
      result.notes = false;
      result.flex = forceFlex || componentsFlex(customComponents);
      return result;
    }

    // put all the content in a chart wrapper div
    chart.addClass('chart-wrapper');
    chart.wrapInner('<div class="chart-stage"></div>');
    var chartContent = chart.children('.chart-stage');

    // flex the content if appropriate
    result.flex = forceFlex || componentsFlex(components);
    if (result.flex) {
      // add flex classes
      chart.addClass('chart-wrapper-flex');
      chartContent.addClass('chart-stage-flex');

      // additional shim to break out of flexbox sizing
      chartContent.wrapInner('<div class="chart-shim"></div>');
      chartContent = chartContent.children('.chart-shim');
    }

    // set custom data-padding attribute
    var pad = chart.attr('data-padding');
    if (pad) {
      if (pad === "0")
        chart.addClass('no-padding');
      else {
        pad = pad + 'px';
        chartContent.css('left', pad)
                    .css('top', pad)
                    .css('right', pad)
                    .css('bottom', pad)
      }
    }

    // call compoents
    componentsLayout(components, title, chartContent);

    // also activate components on shiny output
    findShinyOutput(chartContent).on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {

          // see if we opted out of flex based on our output (for shiny
          // we can't tell what type of output we have until after the
          // value is bound)
          var components = componentsFind(element);
          var flex = forceFlex || componentsFlex(components);
          if (!flex) {
            chart.css('height', "");
            setFlex(chart, "");
            chart.removeClass('chart-wrapper-flex');
            chartContent.removeClass('chart-stage-flex');
            chartContent.children().unwrap();
          }

          // perform layout
          componentsLayout(components, title, element.parent());
        }, 10);
      });

    // add the title
    var chartTitle = $('<div class="chart-title"></div>');
    chartTitle.append(title);
    chart.prepend(chartTitle);

    // add the notes section
    var chartNotes = $('<div class="chart-notes"></div>');
    chartNotes.html('&nbsp;');
    chart.append(chartNotes);

    // attempt to extract notes if we have a component
    if (components.length)
      result.notes = extractChartNotes(chartContent, chartNotes);

    // return result
    return result;
  }

  // build a tabset from a section div with the .tabset class
  function layoutTabset(tabset) {

    // check for fade option
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it and grab it's text
      var heading = tab.find('h' + tabLevel + ':first');
      var headingDom = heading.contents();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab" class="nav-link"></a>');
      a.append(headingDom);
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation" class="nav-item"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      tab.addClass('no-title');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children()[activeTab]).tab("show");
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    // add nav-tabs-custom
    tabset.addClass('nav-tabs-custom');

    // internal layout is dashboard-column with tab-content flexing
    tabset.addClass('dashboard-column');
    setFlex(tabContent, 1);
  }

  // one time global initialization for components
  function componentsInit(dashboardContainer) {
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.init)
        component.init(dashboardContainer);
    }
  }

  // find components that apply within a container
  function componentsFind(container) {

    // look for components
    var components = [];
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.find(container).length)
        components.push(component);
    }

    // if there were none then use a special flowing content component
    // that just adds a scrollbar in fillPage mode
    if (components.length == 0) {
      components.push({
        find: function(container) {
          return container;
        },

        flex: function(fillPage) {
          return fillPage;
        },

        layout: function(title, container, element, fillPage) {
          if (fillPage) {
            container.addClass('flowing-content-shim');
            container.addClass('flowing-content-container');
          }
        }
      });
    }

    return components;
  }

  // if there is a custom component then pick it out
  function componentsCustom(components) {
    var customComponent = [];
    for (var i=0; i<components.length; i++)
      if (components[i].type === "custom") {
        customComponent.push(components[i]);
        break;
      }
    return customComponent;
  }

  // query all components for flex
  function componentsFlex(components) {

    // no components at all means no flex
    if (components.length === 0)
      return false;

    // otherwise query components (assume true unless we see false)
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++)
      if (components[i].flex && !components[i].flex(_options.fillPage))
        return false;
    return true;
  }

  // layout all components
  function componentsLayout(components, title, container) {
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++) {
      var element = components[i].find(container);
      if (components[i].layout) {
        // call layout (don't call other components if it returns false)
        var result = components[i].layout(title, container, element, _options.fillPage);
        if (result === false)
          return;
      }
    }
  }

  // get a reference to the h3, discover it's inner html, and remove it
  function extractTitle(container) {
    var h3 = container.children('h3').first();
    var title = '';
    if (!container.hasClass('no-title'))
      title = h3.contents();
    h3.detach();
    return title;
  }

  // extract chart notes
  function extractChartNotes(chartContent, chartNotes) {
    // look for a terminating blockquote or image caption
    var blockquote = chartContent.children('blockquote:last-child');
    var caption = chartContent.children('div.image-container')
                              .children('p.caption');
    if (blockquote.length) {
      chartNotes.empty().append(blockquote.children('p:first-child').contents());
      blockquote.remove();
      return true;
    } else if (caption.length) {
      chartNotes.empty().append(caption.contents());
      caption.remove();
      return true;
    } else {
      return false;
    }
  }

  function findShinyOutput(chartContent) {
    return chartContent.find('.shiny-text-output, .shiny-html-output');
  }

  // safely detect rendering on a mobile phone
  function isMobilePhone() {
    try
    {
      return ! window.matchMedia("only screen and (min-width: 768px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  function isFillPage() {
    return _options.fillPage;
  }

  // detect portrait mode
  function isPortrait() {
    return ($(window).width() < $(window).height());
  }

  // safely detect rendering on a tablet
  function isTablet() {
    try
    {
      return window.matchMedia("only screen and (min-width: 769px) and (max-width: 992px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  // test whether this is a shiny doc
  function isShinyDoc() {
    return (typeof(window.Shiny) !== "undefined" && !!window.Shiny.outputBindings);
  }

  // set flex using vendor specific prefixes
  function setFlex(el, flex) {
    el.css('-webkit-box-flex', flex)
      .css('-webkit-flex', flex)
      .css('-ms-flex', flex)
      .css('flex', flex);
  }

  // support bookmarking of pages
  function handleLocationHash() {

    // restore tab/page from bookmark
    var hash = window.decodeURIComponent(window.location.hash);
    if (hash.length > 0)
      $('ul.nav a[href="' + hash + '"]').tab('show');
    FlexDashboardUtils.manageActiveNavbarMenu();

    // navigate to a tab when the history changes
    window.addEventListener("popstate", function(e) {
      var hash = window.decodeURIComponent(window.location.hash);
      var activeTab = $('ul.nav a[href="' + hash + '"]');
      if (activeTab.length) {
        activeTab.tab('show');
      } else {
        $('ul.nav a:first').tab('show');
      }
      FlexDashboardUtils.manageActiveNavbarMenu();
    });

    // add a hash to the URL when the user clicks on a tab/page
    $('.navbar-nav a[data-toggle="tab"]').on('click', function(e) {
      var baseUrl = FlexDashboardUtils.urlWithoutHash(window.location.href);
      var hash = FlexDashboardUtils.urlHash($(this).attr('href'));
      var href = baseUrl + hash;
      FlexDashboardUtils.setLocation(href);
    });

    // handle clicks of other links that should activate pages
    var navPages = $('ul.navbar-nav li a[data-toggle=tab]');
    navPages.each(function() {
      var href =  $(this).attr('href');
      var links = $('a[href="' + href + '"][data-toggle!=tab]');
      links.each(function() {
        $(this).on('click', function(e) {
          window.FlexDashboardUtils.showPage(href);
        });
      });
    });
  }

  // tweak Prism highlighting
  function initPrismHighlighting() {

    if (window.Prism) {
      Prism.languages.insertBefore('r', 'comment', {
        'heading': [
          {
            // title 1
        	  // =======

        	  // title 2
        	  // -------
        	  pattern: /\w+.*(?:\r?\n|\r)(?:====+|----+)/,
            alias: 'operator'
          },
          {
            // ### title 3
            pattern: /(^\s*)###[^#].+/m,
            lookbehind: true,
            alias: 'operator'
          }
        ]
      });

      // prism highlight
      Prism.highlightAll();
    }
  }

  FlexDashboard.prototype = {
    constructor: FlexDashboard,
    init: init,
    isMobilePhone: isMobilePhone,
    isFillPage: isFillPage
  };

  return FlexDashboard;

})();

// utils
window.FlexDashboardUtils = {
  resizableImage: function(img) {
    var src = img.attr('src');
    var url = 'url("' + src + '")';
    img.parent().css('background', url)
                .css('background-size', 'contain')
                .css('background-repeat', 'no-repeat')
                .css('background-position', 'center')
                .addClass('image-container');
  },
  setLocation: function(href) {
    if (history && history.pushState) {
      history.pushState(null, null, href);
    } else {
      window.location.replace(href);
    }
    setTimeout(function() {
        window.scrollTo(0, 0);
    }, 10);
    this.manageActiveNavbarMenu();
  },
  showPage: function(href) {
    $('ul.navbar-nav li a[href="' + href + '"]').tab('show');
    var baseUrl = this.urlWithoutHash(window.location.href);
    var loc = baseUrl + href;
    this.setLocation(loc);
  },
  showLinkedValue: function(href) {
    // check for a page link
    if ($('ul.navbar-nav li a[data-toggle=tab][href="' + href + '"]').length > 0)
      this.showPage(href);
    else
      window.open(href);
  },
  urlWithoutHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(0, hashLoc);
    else
      return url;
  },
  urlHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(hashLoc);
    else
      return "";
  },
  manageActiveNavbarMenu: function () {
    // remove active from currently active tabs
    $('.navbar ul.nav .active').removeClass('active');
    // find the active tab
    var activeTab = $('.dashboard-page-wrapper.tab-pane.active');
    if (activeTab.length > 0) {
      var tabId = activeTab.attr('id');
      if (tabId)
        $(".navbar ul.nav a[href='#" + tabId + "']").tab("show");
    }
  }
};

window.FlexDashboard = new FlexDashboard();

// empty content
window.FlexDashboardComponents.push({
  find: function(container) {
    if (container.find('p').length == 0)
      return container;
    else
      return $();
  }
})

// plot image
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('p')
                    .children('img:only-child');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// plot image (figure style)
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.figure').children('img');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// htmlwidget
window.FlexDashboardComponents.push({

  init: function(dashboardContainer) {
    // trigger "shown" after initial layout to force static htmlwidgets
    // in runtime: shiny to be resized after the dom has been transformed
    dashboardContainer.on('flexdashboard:layoutcomplete', function(event) {
      setTimeout(function() {
        dashboardContainer.trigger('shown');
      }, 200);
    });
  },

  find: function(container) {
    return container.children('div[id^="htmlwidget-"],div.html-widget');
  }
});

// gauge
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.html-widget.gauge');
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {


  }

});

// shiny output
window.FlexDashboardComponents.push({
  find: function(container) {
    return container.children('div[class^="shiny-"]');
  }
});

// bootstrap table
window.FlexDashboardComponents.push({

  find: function(container) {
    var bsTable = container.find('table.table');
    if (bsTable.length !== 0)
      return bsTable;
    else
      return container.find('tr.header').parent('thead').parent('table');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var bsTable = element;

    // fixup xtable generated tables with a proper thead
    var headerRow = bsTable.find('tbody > tr:first-child > th').parent();
    if (headerRow.length > 0) {
      var thead = $('<thead></thead>');
      bsTable.prepend(thead);
      headerRow.detach().appendTo(thead);
    }

    // improve appearance
    container.addClass('bootstrap-table');

    // for fill page provide scrolling w/ sticky headers
    if (fillPage) {
      // force scrollbar on overflow
      container.addClass('flowing-content-shim');

      // stable table headers when scrolling
      bsTable.stickyTableHeaders({
        scrollableArea: container
      });
    }
  }
});

// embedded shiny app
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('iframe.shiny-frame');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage) {
      element.attr('height', '100%');
    } else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (!height)
        height = element.attr('height');
      if (!height)
        element.attr('height', 500);
    }
  }
});

// shiny fillRow or fillCol
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('.flexfill-container');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage)
      element.css('height', '100%');
    else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (height === "100%" || height === "auto" || height === "initial" ||
          height === "inherit" || !height) {
        element.css('height', 500);
      }
    }
  }
});

// valueBox
window.FlexDashboardComponents.push({

  type: "custom",

  find: function(container) {
    if (container.find('span.value-output, .shiny-valuebox-output').length)
      return container;
    else
      return $();
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var chartTitle = title;
    var valueBox = element;

    // add value-box class to container
    container.addClass('value-box');

    // value paragraph
    var value = $('<p class="value"></p>');

    // if we have shiny-text-output then just move it in
    var valueOutputSpan = [];
    var shinyOutput = valueBox.find('.shiny-valuebox-output').detach();
    if (shinyOutput.length) {
      valueBox.children().remove();
      shinyOutput.html("&mdash;");
      value.append(shinyOutput);
    } else {
      // extract the value (remove leading vector index)
      var chartValue = valueBox.text().trim();
      chartValue = chartValue.replace("[1] ", "");
      valueOutputSpan = valueBox.find('span.value-output').detach();
      valueBox.children().remove();
      value.text(chartValue);
    }

    // caption
    var caption = $('<p class="caption"></p>');
    caption.append(chartTitle);

    // build inner div for value box and add it
    var inner = $('<div class="inner"></div>');
    inner.append(value);
    inner.append(caption);
    valueBox.append(inner);

    // add icon if specified
    var icon = $('<div class="icon"><i></i></div>');
    valueBox.append(icon);
    function setIcon(chartIcon) {
      var iconLib = "";
      var iconSplit = chartIcon.split(" ");
      if (iconSplit.length > 1) {
        iconLib = iconSplit[0];
        chartIcon = iconSplit.slice(1).join(" ");
      } else {
        var components = chartIcon.split("-");
        if (components.length > 1)
          iconLib = components[0];
      }
      icon.children('i').attr('class', iconLib + ' ' + chartIcon);
    }
    var chartIcon = valueBox.attr('data-icon');
    if (chartIcon)
      setIcon(chartIcon);

    // handle data attributes in valueOutputSpan
    function handleValueOutput(valueOutput) {

      // caption
      var dataCaption = valueOutput.attr('data-caption');
      if (dataCaption)
        caption.html(dataCaption);

      // icon
      var dataIcon = valueOutput.attr('data-icon');
      if (dataIcon)
        setIcon(dataIcon);

      // If valueBox(color=) was an accent color, this attr should
      // be populated with the accent color and the relevant CSS comes
      // in through HTML dependencies
      var dataColorAccent = valueOutput.attr('data-color-accent');
      var valueBoxClasses = "value-box-" + (["primary", "info", "danger", "warning", "success"].join(" value-box-"));
      if (dataColorAccent) {
        valueBox.removeClass(valueBoxClasses);
        valueBox.addClass('value-box-' + dataColorAccent);
      }

      // If valueBox(color=) was a CSS color, these other data-color-*
      // attrs will be populated
      var dataColor = valueOutput.attr('data-color');
      if (dataColor) {
        valueBox.removeClass(valueBoxClasses);
        valueBox.css('background-color', dataColor);
      }
      var dataColorText = valueOutput.attr('data-color-text');
      if (dataColorText) {
        valueBox.find(".inner").css('color', dataColorText);
      }
      var dataColorIcon = valueOutput.attr('data-color-icon');
      if (dataColorIcon) {
        valueBox.find(".icon").css('color', dataColorIcon);
      }

      // url
      var dataHref = valueOutput.attr('data-href');
      if (dataHref) {
        valueBox.addClass('linked-value');
        valueBox.off('click.value-box');
        valueBox.on('click.value-box', function(e) {
          window.FlexDashboardUtils.showLinkedValue(dataHref);
        });
      }
    }

    // check for a valueOutputSpan
    if (valueOutputSpan.length > 0) {
      handleValueOutput(valueOutputSpan);
    }

    // if we have a shinyOutput then bind a listener to handle
    // new valueOutputSpan values
    shinyOutput.on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {
          var valueOutputSpan = element.find('span.value-output');
          if (valueOutputSpan.length > 0)
            handleValueOutput(valueOutputSpan);
        }, 10);
      }
    );
  }
});
</script>

<div id="dashboard-container">

<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<style type="text/css">
table {
  margin: auto;
  border-top: 1px solid #666;
  border-bottom: 1px solid #666;
}
table thead th { border-bottom: 1px solid #ddd; }
th, td { padding: 5px; }

pre {
  white-space: pre-wrap;
  word-break: keep-all;
}

/* Hack to make prompt-tab scrollable again */
div.level3.tab-pane .chart-stage {
  overflow: scroll;
}
</style>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="column" class="section level2" data-width="55">
<h2>Column</h2>
<div id="score-comparisons-of-112-publications" class="section level3">
<h3>Score comparisons of 112 publications</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div class="datatables html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-4e2656735600ceb103f6" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-4e2656735600ceb103f6">{"x":{"filter":"none","vertical":false,"fillContainer":true,"data":[["61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","170","171","172"],["<a href='#61' title='Jump to individual results on the right'>Aikenhead 2011<\/a>","<a href='#62' title='Jump to individual results on the right'>Al-Hozaim 2010<\/a>","<a href='#63' title='Jump to individual results on the right'>Allen 2015<\/a>","<a href='#64' title='Jump to individual results on the right'>Allin 2015<\/a>","<a href='#65' title='Jump to individual results on the right'>Alzahem 2011<\/a>","<a href='#66' title='Jump to individual results on the right'>Apelt 2013<\/a>","<a href='#67' title='Jump to individual results on the right'>Aworanti 2014<\/a>","<a href='#68' title='Jump to individual results on the right'>Baker 2015<\/a>","<a href='#69' title='Jump to individual results on the right'>Berger 2012<\/a>","<a href='#70' title='Jump to individual results on the right'>Billingham 2010<\/a>","<a href='#71' title='Jump to individual results on the right'>Black 2013<\/a>","<a href='#72' title='Jump to individual results on the right'>Borruto 2010<\/a>","<a href='#73' title='Jump to individual results on the right'>Castagnetti 2010<\/a>","<a href='#74' title='Jump to individual results on the right'>Castagnetti 2016<\/a>","<a href='#75' title='Jump to individual results on the right'>Chan 2014 (Pediatr Surg Int)<\/a>","<a href='#76' title='Jump to individual results on the right'>Chan 2014 (J Pediatr Surg)<\/a>","<a href='#77' title='Jump to individual results on the right'>Chang 2015<\/a>","<a href='#78' title='Jump to individual results on the right'>Chen 2013<\/a>","<a href='#79' title='Jump to individual results on the right'>Corbett 2015<\/a>","<a href='#80' title='Jump to individual results on the right'>Cullis 2016<\/a>","<a href='#81' title='Jump to individual results on the right'>Cundy 2014 (BJU Int)<\/a>","<a href='#82' title='Jump to individual results on the right'>Cundy 2014 (J Pediatr Surg)<\/a>","<a href='#83' title='Jump to individual results on the right'>Cundy 2014 (Eur J Pediatr Surg)<\/a>","<a href='#84' title='Jump to individual results on the right'>Ding 2013<\/a>","<a href='#85' title='Jump to individual results on the right'>Dingemann 2014<\/a>","<a href='#86' title='Jump to individual results on the right'>Dingemann 2013<\/a>","<a href='#87' title='Jump to individual results on the right'>Ells 2015<\/a>","<a href='#88' title='Jump to individual results on the right'>Elyas 2010<\/a>","<a href='#89' title='Jump to individual results on the right'>Esposito 2014<\/a>","<a href='#90' title='Jump to individual results on the right'>Feng 2016<\/a>","<a href='#91' title='Jump to individual results on the right'>Feng 2015<\/a>","<a href='#92' title='Jump to individual results on the right'>Friedmacher 2011<\/a>","<a href='#93' title='Jump to individual results on the right'>Friedmacher 2012<\/a>","<a href='#94' title='Jump to individual results on the right'>Frongia 2013<\/a>","<a href='#95' title='Jump to individual results on the right'>Gallo 2012<\/a>","<a href='#96' title='Jump to individual results on the right'>Gosemann 2013<\/a>","<a href='#97' title='Jump to individual results on the right'>Graziano 2015<\/a>","<a href='#98' title='Jump to individual results on the right'>Guo 2011<\/a>","<a href='#99' title='Jump to individual results on the right'>Hall 2011<\/a>","<a href='#100' title='Jump to individual results on the right'>Healy 2015<\/a>","<a href='#101' title='Jump to individual results on the right'>Healy 2016<\/a>","<a href='#102' title='Jump to individual results on the right'>Heloury 2012<\/a>","<a href='#103' title='Jump to individual results on the right'>Huang 2015<\/a>","<a href='#104' title='Jump to individual results on the right'>Ishii 2014<\/a>","<a href='#105' title='Jump to individual results on the right'>Ishii 2015<\/a>","<a href='#106' title='Jump to individual results on the right'>Ito 2014<\/a>","<a href='#107' title='Jump to individual results on the right'>Jia 2011<\/a>","<a href='#108' title='Jump to individual results on the right'>Kapralik 2016<\/a>","<a href='#109' title='Jump to individual results on the right'>Kunz 2013<\/a>","<a href='#110' title='Jump to individual results on the right'>Landisch 2015<\/a>","<a href='#111' title='Jump to individual results on the right'>Lane 2010<\/a>","<a href='#112' title='Jump to individual results on the right'>Lansdale 2010<\/a>","<a href='#113' title='Jump to individual results on the right'>Lee 2010<\/a>","<a href='#114' title='Jump to individual results on the right'>LeeVan 2016<\/a>","<a href='#115' title='Jump to individual results on the right'>Liang 2011<\/a>","<a href='#116' title='Jump to individual results on the right'>Lishuang 2015<\/a>","<a href='#117' title='Jump to individual results on the right'>Livingston 2015<\/a>","<a href='#118' title='Jump to individual results on the right'>Mauritz 2013<\/a>","<a href='#119' title='Jump to individual results on the right'>Mauritz 2011<\/a>","<a href='#120' title='Jump to individual results on the right'>Mei 2011<\/a>","<a href='#121' title='Jump to individual results on the right'>Mullassery 2014<\/a>","<a href='#122' title='Jump to individual results on the right'>Nagler 2011<\/a>","<a href='#123' title='Jump to individual results on the right'>Narayanan 2013<\/a>","<a href='#124' title='Jump to individual results on the right'>Nasr 2010<\/a>","<a href='#125' title='Jump to individual results on the right'>Nasr 2013<\/a>","<a href='#126' title='Jump to individual results on the right'>Nataraja 2013<\/a>","<a href='#127' title='Jump to individual results on the right'>Nicolau 2011<\/a>","<a href='#128' title='Jump to individual results on the right'>Oliveira 2016<\/a>","<a href='#129' title='Jump to individual results on the right'>Oomen 2012<\/a>","<a href='#130' title='Jump to individual results on the right'>Parolini 2016<\/a>","<a href='#131' title='Jump to individual results on the right'>Parolini 2014<\/a>","<a href='#132' title='Jump to individual results on the right'>Peters 2013<\/a>","<a href='#133' title='Jump to individual results on the right'>Peycelon 2014<\/a>","<a href='#134' title='Jump to individual results on the right'>Pfistermuller 2015<\/a>","<a href='#135' title='Jump to individual results on the right'>Puligandla 2015<\/a>","<a href='#136' title='Jump to individual results on the right'>Reddy 2010<\/a>","<a href='#137' title='Jump to individual results on the right'>Romao 2012<\/a>","<a href='#138' title='Jump to individual results on the right'>Ross 2015<\/a>","<a href='#139' title='Jump to individual results on the right'>Ruttenstock 2010<\/a>","<a href='#140' title='Jump to individual results on the right'>Rynja 2011<\/a>","<a href='#141' title='Jump to individual results on the right'>Saldaa 2013<\/a>","<a href='#142' title='Jump to individual results on the right'>Sauerland 2010<\/a>","<a href='#143' title='Jump to individual results on the right'>Scholfield 2016<\/a>","<a href='#144' title='Jump to individual results on the right'>Sharp 2015<\/a>","<a href='#145' title='Jump to individual results on the right'>Shawyer 2014<\/a>","<a href='#146' title='Jump to individual results on the right'>Shawyer 2015<\/a>","<a href='#147' title='Jump to individual results on the right'>Shen 2015<\/a>","<a href='#148' title='Jump to individual results on the right'>Siddiqui 2011<\/a>","<a href='#149' title='Jump to individual results on the right'>Siminas 2015<\/a>","<a href='#150' title='Jump to individual results on the right'>Sklar 2014<\/a>","<a href='#151' title='Jump to individual results on the right'>Sola 2010<\/a>","<a href='#152' title='Jump to individual results on the right'>Symeonidis 2016<\/a>","<a href='#153' title='Jump to individual results on the right'>Tan 2016<\/a>","<a href='#154' title='Jump to individual results on the right'>Terui 2015<\/a>","<a href='#155' title='Jump to individual results on the right'>Thomson 2015<\/a>","<a href='#156' title='Jump to individual results on the right'>Thyoka 2013<\/a>","<a href='#157' title='Jump to individual results on the right'>van Dalen 2015<\/a>","<a href='#158' title='Jump to individual results on the right'>Vanden Berg 2016<\/a>","<a href='#159' title='Jump to individual results on the right'>van den Hondel 2014<\/a>","<a href='#160' title='Jump to individual results on the right'>Vernon-Roberts 2013<\/a>","<a href='#161' title='Jump to individual results on the right'>Wang 2013<\/a>","<a href='#162' title='Jump to individual results on the right'>Wayne 2015<\/a>","<a href='#163' title='Jump to individual results on the right'>Weih 2012<\/a>","<a href='#164' title='Jump to individual results on the right'>Wenk 2015<\/a>","<a href='#165' title='Jump to individual results on the right'>Wilkinson 2012<\/a>","<a href='#166' title='Jump to individual results on the right'>Wright 2013<\/a>","<a href='#167' title='Jump to individual results on the right'>Yang 2011<\/a>","<a href='#168' title='Jump to individual results on the right'>Yang 2013<\/a>","<a href='#169' title='Jump to individual results on the right'>Youssef 2016<\/a>","<a href='#170' title='Jump to individual results on the right'>Zani 2015<\/a>","<a href='#171' title='Jump to individual results on the right'>Zhao 2015<\/a>","<a href='#172' title='Jump to individual results on the right'>Zhu 2016<\/a>"],[0.84,0.777777777777778,0.807692307692308,0.923076923076923,0.740740740740741,0.846153846153846,0.807692307692308,0.814814814814815,0.8,0.62962962962963,0.666666666666667,0.76,0.703703703703704,0.64,0.777777777777778,0.740740740740741,0.619047619047619,0.923076923076923,0.833333333333333,0.846153846153846,0.72,0.92,0.541666666666667,0.555555555555556,0.84,0.884615384615385,0.807692307692308,0.84,0.814814814814815,0.777777777777778,0.703703703703704,0.625,0.703703703703704,0.846153846153846,0.730769230769231,0.740740740740741,0.730769230769231,0.769230769230769,0.75,0.8,0.851851851851852,0.888888888888889,0.576923076923077,0.88,0.777777777777778,0.615384615384615,0.846153846153846,0.777777777777778,0.875,0.807692307692308,0.851851851851852,0.653846153846154,0.814814814814815,0.666666666666667,0.666666666666667,0.653846153846154,0.653846153846154,0.807692307692308,0.923076923076923,0.8,0.692307692307692,0.653846153846154,0.851851851851852,0.769230769230769,0.615384615384615,0.807692307692308,0.777777777777778,0.703703703703704,0.703703703703704,0.769230769230769,0.846153846153846,0.777777777777778,0.814814814814815,0.565217391304348,0.772727272727273,0.703703703703704,0.692307692307692,0.692307692307692,0.592592592592593,0.769230769230769,0.703703703703704,0.925925925925926,0.56,0.807692307692308,0.916666666666667,0.740740740740741,0.62962962962963,0.76,0.666666666666667,0.62962962962963,0.730769230769231,0.692307692307692,0.91304347826087,0.615384615384615,0.703703703703704,0.923076923076923,0.8,0.777777777777778,0.538461538461538,0.851851851851852,0.653846153846154,0.777777777777778,0.777777777777778,0.739130434782609,0.769230769230769,0.64,0.653846153846154,0.769230769230769,0.75,0.769230769230769,0.703703703703704,0.807692307692308],[0.739759036144578,0.665979381443299,0.707792207792208,0.796992481203007,0.511627906976744,0.765217391304348,0.714587737843552,0.539249146757679,0.688940092165899,0.420600858369099,0.373711340206186,0.621495327102804,0.552795031055901,0.362204724409449,0.622377622377622,0.422018348623853,0.287128712871287,0.848314606741573,0.720930232558139,0.6991643454039,-0.105263157894737,0.625,0.197297297297297,0.164948453608247,0.763676148796499,0.825431034482759,0.578125,0.578125,0.720496894409938,0.610576923076923,0.488151658767773,0.381679389312977,0.518930957683742,0.764705882352941,0.56651376146789,0.607068607068607,0.597014925373134,0.423487544483986,0.630979498861048,0.519572953736655,0.77639751552795,0.793367346938776,0.144092219020173,0.811188811188811,0.653846153846154,0.309462915601023,0.644736842105263,0.406593406593407,0.642384105960265,0.704595185995624,0.716535433070866,0.332417582417582,0.712153518123667,0.503067484662577,0.319327731092437,0.256880733944954,0.315492957746479,0.529616724738676,0.859007832898172,0.599406528189911,0.416216216216216,0.093283582089552,0.707317073170732,0.585677749360614,0.386363636363636,0.604105571847507,0.653846153846154,0.552795031055901,0.465346534653465,0.63677130044843,0.752293577981651,0.64,0.660804020100503,0.386363636363636,0.633152173913043,0.504587155963303,0.466666666666667,0.455919395465995,0.3125,0.651612903225806,0.553719008264463,0,0.320366132723112,0.670731707317073,0.858267716535433,0.479338842975207,0.366197183098592,0.395522388059701,0.501026694045175,0.366197183098592,0.384364820846905,0.505720823798627,0.841176470588235,0.230769230769231,0.23943661971831,0.878103837471783,0.642857142857143,0.64,0.246511627906977,0.675675675675676,0.187290969899666,0.625,0.64,0.369649805447471,0.635135135135135,0.319327731092437,0.383248730964467,0.654584221748401,0.352,0.63431151241535,0.458646616541353,0.665012406947891],[0.0740740740740741,0,0.037037037037037,0.037037037037037,0,0.037037037037037,0.037037037037037,0,0.0740740740740741,0,0,0.0740740740740741,0,0.0740740740740741,0,0,0.222222222222222,0.037037037037037,0.111111111111111,0.037037037037037,0.0740740740740741,0.0740740740740741,0.111111111111111,0,0.0740740740740741,0.037037037037037,0.037037037037037,0.0740740740740741,0,0,0,0.111111111111111,0,0.037037037037037,0.037037037037037,0,0.037037037037037,0.037037037037037,0.111111111111111,0.0740740740740741,0,0,0.037037037037037,0.0740740740740741,0,0.037037037037037,0.037037037037037,0,0.407407407407407,0.037037037037037,0,0.037037037037037,0,0,0,0.037037037037037,0.037037037037037,0.037037037037037,0.037037037037037,0.0740740740740741,0.037037037037037,0.037037037037037,0,0.037037037037037,0.037037037037037,0.037037037037037,0,0,0,0.037037037037037,0.037037037037037,0,0,0.148148148148148,0.185185185185185,0,0.037037037037037,0.037037037037037,0,0.037037037037037,0,0,0.0740740740740741,0.037037037037037,0.111111111111111,0,0,0.0740740740740741,0,0,0.037037037037037,0.037037037037037,0.148148148148148,0.037037037037037,0,0.037037037037037,0.0740740740740741,0,0.037037037037037,0,0.037037037037037,0,0,0.148148148148148,0.037037037037037,0.0740740740740741,0.037037037037037,0.037037037037037,0.111111111111111,0.037037037037037,0,0.037037037037037],[0.8,0.9,0.818181818181818,0.8,0.818181818181818,0.818181818181818,0.9,0.777777777777778,0.909090909090909,0.8,0.8,0.545454545454545,0.636363636363636,0.7,0.9,0.9,0.818181818181818,0.727272727272727,0.8,0.9,0.818181818181818,0.7,0.545454545454545,0.8,0.9,0.6,0.9,0.727272727272727,0.7,0.8,0.666666666666667,0.636363636363636,0.777777777777778,0.818181818181818,0.727272727272727,0.7,0.6,0.5,0.636363636363636,0.818181818181818,0.909090909090909,0.909090909090909,0.666666666666667,0.6,0.636363636363636,0.636363636363636,0.5,0.636363636363636,0.545454545454545,0.636363636363636,0.909090909090909,0.6,0.818181818181818,0.6,0.7,0.818181818181818,0.545454545454545,0.8,0.7,0.9,0.909090909090909,0.8,0.9,0.727272727272727,0.727272727272727,0.636363636363636,0.454545454545455,0.818181818181818,0.818181818181818,0.818181818181818,0.818181818181818,0.818181818181818,0.818181818181818,0.555555555555556,0.818181818181818,0.909090909090909,0.7,0.8,0.454545454545455,0.7,0.727272727272727,0.909090909090909,0.6,0.6,0.545454545454545,0.636363636363636,0.636363636363636,0.666666666666667,0.8,0.7,0.545454545454545,0.727272727272727,0.777777777777778,0.555555555555556,0.727272727272727,0.636363636363636,0.777777777777778,0.8,0.5,1,0.7,1,0.8,0.7,0.727272727272727,0.9,0.818181818181818,0.818181818181818,0.818181818181818,0.727272727272727,0.818181818181818,0.7],[0.671641791044776,0.830769230769231,0.666666666666667,0.488372093023256,0.607142857142857,0.666666666666667,0.8,0.541666666666667,0.810344827586207,0.6,0.645161290322581,0,0.3125,0.388888888888889,0.833333333333333,0.792452830188679,0.607142857142857,0.476190476190476,0.685714285714286,0.830769230769231,0.388888888888889,0.266666666666667,0.166666666666667,0.607142857142857,0.819672131147541,0.380281690140845,0.738095238095238,0.232558139534884,0.421052631578947,0.6,0.388888888888889,0.371428571428571,0.521739130434783,0.661538461538462,0.521739130434783,0.352941176470588,0.405405405405405,-0.0185185185185186,0.323076923076923,0.607142857142857,0.813559322033898,0.744186046511628,0.365384615384615,0.301587301587302,0.443037974683544,0.290322580645161,0.0434782608695651,0.241379310344828,0.236111111111111,0.476190476190476,0.744186046511628,0.214285714285714,0.702702702702703,0.3125,0.388888888888889,0.633333333333333,0.266666666666667,0.584905660377358,0.528571428571429,0.803571428571429,0.813559322033898,0,0.8,0.440677966101695,0.541666666666667,0.333333333333333,0.0434782608695653,0.584905660377358,0.620689655172414,0.666666666666667,0.717948717948718,0.698630136986301,0.576923076923077,0.0434782608695651,0.710526315789474,0.813559322033898,0.4,0.592592592592593,0.0149253731343283,0.459016393442623,0.521739130434783,0,0.2,0.428571428571429,0.285714285714286,0.241379310344828,0.290322580645161,0.3125,0.685714285714286,0.459016393442623,0.166666666666667,0.597560975609756,0.521739130434783,0.228070175438596,0.421052631578947,0.443037974683544,0.645161290322581,0.685714285714286,0.228070175438596,1,0.388888888888889,1,0.56,0.4,0.45,0.725,0.633333333333333,0.702702702702703,0.541666666666667,0.541666666666667,0.620689655172414,0.4],[0.0909090909090909,0.0909090909090909,0,0.0909090909090909,0,0,0.0909090909090909,0.181818181818182,0,0.0909090909090909,0.0909090909090909,0,0,0.0909090909090909,0.0909090909090909,0.0909090909090909,0,0,0.0909090909090909,0.0909090909090909,0,0.0909090909090909,0,0.0909090909090909,0.0909090909090909,0.0909090909090909,0.0909090909090909,0,0.0909090909090909,0.0909090909090909,0.181818181818182,0,0.181818181818182,0,0,0.0909090909090909,0.0909090909090909,0.0909090909090909,0,0,0,0,0.181818181818182,0.0909090909090909,0,0,0.272727272727273,0,0,0,0,0.0909090909090909,0,0.0909090909090909,0.0909090909090909,0,0,0.0909090909090909,0.0909090909090909,0.0909090909090909,0,0.0909090909090909,0.0909090909090909,0,0,0,0,0,0,0,0,0,0,0.181818181818182,0,0,0.0909090909090909,0.0909090909090909,0,0.0909090909090909,0,0,0.0909090909090909,0.0909090909090909,0,0,0,0.181818181818182,0.0909090909090909,0.0909090909090909,0,0,0.181818181818182,0.181818181818182,0,0,0.181818181818182,0.0909090909090909,0.272727272727273,0.0909090909090909,0.0909090909090909,0,0.0909090909090909,0.0909090909090909,0,0.0909090909090909,0,0,0,0,0,0.0909090909090909]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th>Ref.<\/th>\n      <th>Author & Year<\/th>\n      <th>PRISMA agreement<\/th>\n      <th>PRISMA <\/th>\n      <th>PRISMA deferral<\/th>\n      <th>AMSTAR agreement<\/th>\n      <th>AMSTAR <\/th>\n      <th>AMSTAR deferral<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"bPaginate":false,"dom":"t","order":[[0,"asc"]],"columnDefs":[{"targets":3,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":6,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":2,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatPercentage(data, 0, 3, \",\", \".\", null);\n  }"},{"targets":4,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatPercentage(data, 0, 3, \",\", \".\", null);\n  }"},{"targets":5,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatPercentage(data, 0, 3, \",\", \".\", null);\n  }"},{"targets":7,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatPercentage(data, 0, 3, \",\", \".\", null);\n  }"},{"className":"dt-right","targets":[2,3,4,5,6,7]}],"autoWidth":false,"orderClasses":false}},"evals":["options.columnDefs.0.render","options.columnDefs.1.render","options.columnDefs.2.render","options.columnDefs.3.render","options.columnDefs.4.render","options.columnDefs.5.render"],"jsHooks":[]}</script>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
</div>
<div id="score-heatmaps-prisma-amstar" class="section level3"
data-height="720">
<h3>Score heatmaps
(<a onclick="$('p.image-container')[0].style = 'background: url(&quot;../prisma_amstar/llm_consistency_5_prisma_amstar/results/human_consensus_27_items.png&quot;) center center / contain no-repeat;'; $('p.image-container img')[0].src = &quot;../prisma_amstar/llm_consistency_5_prisma_amstar/results/human_consensus_27_items.png&quot;;" style="cursor: pointer">PRISMA</a>
/
<a onclick="$('p.image-container')[0].style = 'background: url(&quot;../prisma_amstar/llm_consistency_5_prisma_amstar/results/human_consensus_11_items.png&quot;) center center / contain no-repeat;'; $('p.image-container img')[0].src = &quot;../prisma_amstar/llm_consistency_5_prisma_amstar/results/human_consensus_11_items.png&quot;;" style="cursor: pointer">AMSTAR</a>)</h3>
<p><img data-figure-id="fig1" src="../prisma_amstar/llm_consistency_5_prisma_amstar/results/human_consensus_27_items.png" width="1536" onclick="window.open(this.src)" style="cursor: pointer"></p>
</div>
</div>
<div id="column-1" class="section level2 tabset" data-width="45">
<h2 class="tabset">Column</h2>
<div id="individual-results" class="section level3">
<h3>Individual results</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<p><a name='61'></a></p>
<div
id="aikenhead-2011-effectiveness-and-cost-effectiveness-of-paediatric-bariatric-surgery-a-systematic-review"
class="section level4">
<h4>61.
<a href='https://doi.org/10.1111/J.1758-8111.2010.00003.X' title='Open publication'>Aikenhead
2011: <i>Effectiveness and cost-effectiveness of paediatric bariatric
surgery: a systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='62'></a></p>
</div>
<div
id="al-hozaim-2010-laparoscopic-assisted-anorectal-pull-through-for-anorectal-malformations-a-systematic-review-and-the-need-for-standardization-of-outcome-reporting"
class="section level4">
<h4>62.
<a href='https://doi.org/10.1016/J.JPEDSURG.2009.12.001' title='Open publication'>Al-Hozaim
2010: <i>Laparoscopic-assisted anorectal pull-through for anorectal
malformations: a systematic review and the need for standardization of
outcome reporting</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='63'></a></p>
</div>
<div
id="allen-2015-pediatric-emergency-department-thoracotomy-a-large-case-series-and-systematic-review"
class="section level4">
<h4>63.
<a href='https://doi.org/10.1016/J.JPEDSURG.2014.10.042' title='Open publication'>Allen
2015: <i>Pediatric emergency department thoracotomy: A large case series
and systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='64'></a></p>
</div>
<div
id="allin-2015-challenges-of-improving-the-evidence-base-in-smaller-surgical-specialties-as-highlighted-by-a-systematic-review-of-gastroschisis-management"
class="section level4">
<h4>64.
<a href='https://doi.org/10.1371/JOURNAL.PONE.0116908' title='Open publication'>Allin
2015: <i>Challenges of Improving the Evidence Base in Smaller Surgical
Specialties, as Highlighted by a Systematic Review of Gastroschisis
Management</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><a name='65'></a></p>
</div>
<div
id="alzahem-2011-laparoscopic-versus-open-inguinal-herniotomy-in-infants-and-children-a-meta-analysis"
class="section level4">
<h4>65.
<a href='https://doi.org/10.1007/S00383-010-2840-X' title='Open publication'>Alzahem
2011: <i>Laparoscopic versus open inguinal herniotomy in infants and
children: a meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='66'></a></p>
</div>
<div
id="apelt-2013-laparoscopic-treatment-of-intussusception-in-children-a-systematic-review"
class="section level4">
<h4>66.
<a href='https://doi.org/10.1016/J.JPEDSURG.2013.05.024' title='Open publication'>Apelt
2013: <i>Laparoscopic treatment of intussusception in children: A
systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='67'></a></p>
</div>
<div
id="aworanti-2014-management-of-recurrent-tracheoesophageal-fistulas-a-systematic-review"
class="section level4">
<h4>67.
<a href='https://doi.org/10.1055/S-0034-1370780' title='Open publication'>Aworanti
2014: <i>Management of Recurrent Tracheoesophageal Fistulas: A
Systematic Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='68'></a></p>
</div>
<div
id="baker-2015-a-systematic-review-and-meta-analysis-of-gastrostomy-insertion-techniques-in-children"
class="section level4">
<h4>68.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.02.021' title='Open publication'>Baker
2015: <i>A systematic review and meta-analysis of gastrostomy insertion
techniques in children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='69'></a></p>
</div>
<div
id="berger-2012-mitomycin-c-in-the-therapy-of-recurrent-esophageal-strictures-hype-or-hope"
class="section level4">
<h4>69.
<a href='https://doi.org/10.1055/S-0032-1311695' title='Open publication'>Berger
2012: <i>Mitomycin C in the Therapy of Recurrent Esophageal Strictures:
Hype or Hope?</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='70'></a></p>
</div>
<div
id="billingham-2010-pediatric-surgical-technique-laparoscopic-or-open-approach-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>70.
<a href='https://doi.org/10.1055/S-0029-1241871' title='Open publication'>Billingham
2010: <i>Pediatric Surgical Technique: Laparoscopic or Open Approach? A
systematic Review and Meta-Analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='71'></a></p>
</div>
<div
id="black-2013-bariatric-surgery-for-obese-children-and-adolescents-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>71.
<a href='https://doi.org/10.1111/OBR.12037' title='Open publication'>Black
2013: <i>Bariatric surgery for obese children and adolescents: a
systematic review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='72'></a></p>
</div>
<div
id="borruto-2010-laparoscopic-vs-open-varicocelectomy-in-children-and-adolescents-review-of-the-recent-literature-and-meta-analysis"
class="section level4">
<h4>72.
<a href='https://doi.org/10.1016/J.JPEDSURG.2010.07.007' title='Open publication'>Borruto
2010: <i>Laparoscopic vs open varicocelectomy in children and
adolescents: review of the recent literature and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='73'></a></p>
</div>
<div
id="castagnetti-2010-surgical-management-of-primary-severe-hypospadias-in-children-systematic-20-year-review"
class="section level4">
<h4>73.
<a href='https://doi.org/10.1016/J.JURO.2010.06.044' title='Open publication'>Castagnetti
2010: <i>Surgical Management of Primary Severe Hypospadias in Children:
Systematic 20-Year Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='74'></a></p>
</div>
<div
id="castagnetti-2016-does-preputial-reconstruction-increase-complication-rate-of-hypospadias-repair-20-year-systematic-review-and-meta-analysis"
class="section level4">
<h4>74.
<a href='https://doi.org/10.3389/FPED.2016.00041' title='Open publication'>Castagnetti
2016: <i>Does Preputial Reconstruction Increase Complication Rate of
Hypospadias Repair? 20-Year Systematic Review and
Meta-Analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='75'></a></p>
</div>
<div
id="chan-2014-pediatr-surg-int-ideal-timing-of-orchiopexy-a-systematic-review"
class="section level4">
<h4>75.
<a href='https://doi.org/10.1007/S00383-013-3429-Y' title='Open publication'>Chan
2014 (Pediatr Surg Int): <i>Ideal timing of orchiopexy: a systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='76'></a></p>
</div>
<div
id="chan-2014-j-pediatr-surg-minimally-invasive-versus-open-repair-of-bochdalek-hernia-a-meta-analysis"
class="section level4">
<h4>76.
<a href='https://doi.org/10.1016/J.JPEDSURG.2014.02.049' title='Open publication'>Chan
2014 (J Pediatr Surg): <i>Minimally invasive versus open repair of
Bochdalek hernia: a meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='77'></a></p>
</div>
<div
id="chang-2015-comparing-the-efficacy-and-safety-between-robotic-assisted-versus-open-pyeloplasty-in-children-a-systemic-review-and-meta-analysis"
class="section level4">
<h4>77.
<a href='https://doi.org/10.1007/S00345-015-1526-3' title='Open publication'>Chang
2015: <i>Comparing the efficacy and safety between robotic-assisted
versus open pyeloplasty in children: a systemic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='78'></a></p>
</div>
<div
id="chen-2013-transanal-endorectal-pull-through-versus-transabdominal-approach-for-hirschsprungs-disease-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>78.
<a href='https://doi.org/10.1016/J.JPEDSURG.2012.12.036' title='Open publication'>Chen
2013: <i>Transanal endorectal pull-through versus transabdominal
approach for Hirschsprungs disease: A systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='79'></a></p>
</div>
<div
id="corbett-2015-outcomes-of-endopyelotomy-for-pelviureteric-junction-obstruction-in-the-paediatric-population-a-systematic-review"
class="section level4">
<h4>79.
<a href='https://doi.org/10.1016/J.JPUROL.2015.08.014' title='Open publication'>Corbett
2015: <i>Outcomes of endopyelotomy for pelviureteric junction
obstruction in the paediatric population: A systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='80'></a></p>
</div>
<div
id="cullis-2016-is-screening-of-intestinal-foregut-anatomy-in-heterotaxy-patients-really-necessary"
class="section level4">
<h4>80.
<a href='https://doi.org/10.1097/sla.0000000000001563' title='Open publication'>Cullis
2016: <i>Is Screening of Intestinal Foregut Anatomy in Heterotaxy
Patients Really Necessary?</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='81'></a></p>
</div>
<div
id="cundy-2014-bju-int-meta-analysis-of-robot-assisted-vs-conventional-laparoscopic-and-open-pyeloplasty-in-children"
class="section level4">
<h4>81.
<a href='https://doi.org/10.1111/bju.12683 ' title='Open publication'>Cundy
2014 (BJU Int): <i>Meta-analysis of robot-assisted vs conventional
laparoscopic and open pyeloplasty in children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><a name='82'></a></p>
</div>
<div
id="cundy-2014-j-pediatr-surg-meta-analysis-of-robot-assisted-versus-conventional-laparoscopic-fundoplication-in-children"
class="section level4">
<h4>82.
<a href='https://doi.org/10.1016/J.JPEDSURG.2013.12.014' title='Open publication'>Cundy
2014 (J Pediatr Surg): <i>Meta analysis of robot-assisted versus
conventional laparoscopic fundoplication in children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='83'></a></p>
</div>
<div
id="cundy-2014-eur-j-pediatr-surg-robot-assisted-minimally-invasive-surgery-for-pediatric-solid-tumors-a-systematic-review-of-feasibility-and-current-status"
class="section level4">
<h4>83.
<a href='https://doi.org/10.1055/S-0033-1347297' title='Open publication'>Cundy
2014 (Eur J Pediatr Surg): <i>Robot-Assisted Minimally Invasive Surgery
for Pediatric Solid Tumors: A Systematic Review of Feasibility and
Current Status</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='84'></a></p>
</div>
<div
id="ding-2013-single-incision-versus-conventional-three-incision-laparoscopic-appendicectomy-for-appendicitis-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>84.
<a href='https://doi.org/10.1016/J.JPEDSURG.2013.01.026' title='Open publication'>Ding
2013: <i>Single-incision versus conventional three-incision laparoscopic
appendicectomy for appendicitis: A systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='85'></a></p>
</div>
<div
id="dingemann-2014-thoracoscopic-procedures-in-pediatric-surgery-what-is-the-evidence"
class="section level4">
<h4>85.
<a href='https://doi.org/10.1055/S-0033-1350060' title='Open publication'>Dingemann
2014: <i>Thoracoscopic Procedures in Pediatric Surgery: What is the
Evidence?</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='86'></a></p>
</div>
<div
id="dingemann-2013-systematic-review-of-level-1-evidence-for-laparoscopic-pediatric-surgery-do-our-procedures-comply-with-the-requirements-of-evidence-based-medicine"
class="section level4">
<h4>86.
<a href='https://doi.org/10.1055/S-0033-1333639' title='Open publication'>Dingemann
2013: <i>Systematic Review of Level 1 Evidence for Laparoscopic
Pediatric Surgery: Do Our Procedures Comply with the Requirements of
Evidence-Based Medicine?</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='87'></a></p>
</div>
<div
id="ells-2015-surgery-for-the-treatment-of-obesity-in-children-and-adolescents"
class="section level4">
<h4>87.
<a href='https://doi.org/10.1002/14651858.CD011740' title='Open publication'>Ells
2015: <i>Surgery for the treatment of obesity in children and
adolescents</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><a name='88'></a></p>
</div>
<div
id="elyas-2010-is-staging-beneficial-for-fowler-stephens-orchiopexy-a-systematic-review"
class="section level4">
<h4>88.
<a href='https://doi.org/10.1016/J.JURO.2010.01.035' title='Open publication'>Elyas
2010: <i>Is Staging Beneficial for Fowler-Stephens Orchiopexy? A
Systematic Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='89'></a></p>
</div>
<div
id="esposito-2014-laparoscopic-versus-open-inguinal-hernia-repair-in-pediatric-patients-a-systematic-review"
class="section level4">
<h4>89.
<a href='https://doi.org/10.1089/lap.2014.0194' title='Open publication'>Esposito
2014: <i>Laparoscopic Versus Open Inguinal Hernia Repair in Pediatric
Patients: A Systematic Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='90'></a></p>
</div>
<div
id="feng-2016-laparoscopic-versus-open-splenectomy-in-children-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>90.
<a href='https://doi.org/10.1007/S00383-015-3845-2' title='Open publication'>Feng
2016: <i>Laparoscopic versus open splenectomy in children: a systematic
review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='91'></a></p>
</div>
<div
id="feng-2015-open-versus-laparoscopic-inguinal-herniotomy-in-children"
class="section level4">
<h4>91.
<a href='https://doi.org/10.1097/SLE.0000000000000161' title='Open publication'>Feng
2015: <i>Open Versus Laparoscopic Inguinal Herniotomy in
Children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='92'></a></p>
</div>
<div
id="friedmacher-2011-residual-aganglionosis-after-pull-through-operation-for-hirschsprungs-disease-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>92.
<a href='https://doi.org/10.1007/S00383-011-2958-5' title='Open publication'>Friedmacher
2011: <i>Residual aganglionosis after pull-through operation for
Hirschsprungs disease: a systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='93'></a></p>
</div>
<div
id="friedmacher-2012-delayed-primary-anastomosis-for-management-of-long-gap-esophageal-atresia-a-meta-analysis-of-complications-and-long-term-outcome"
class="section level4">
<h4>93.
<a href='https://doi.org/10.1007/S00383-012-3142-2' title='Open publication'>Friedmacher
2012: <i>Delayed primary anastomosis for management of long-gap
esophageal atresia: a meta-analysis of complications and long-term
outcome</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='94'></a></p>
</div>
<div
id="frongia-2013-comparison-of-lilt-and-step-procedures-in-children-with-short-bowel-syndrome-a-systematic-review-of-the-literature"
class="section level4">
<h4>94.
<a href='https://doi.org/10.1016/J.JPEDSURG.2013.05.018' title='Open publication'>Frongia
2013: <i>Comparison of LILT and STEP procedures in children with short
bowel syndrome  A systematic review of the literature</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='95'></a></p>
</div>
<div
id="gallo-2012-long-gap-esophageal-atresia-a-meta-analysis-of-jejunal-interposition-colon-interposition-and-gastric-pull-up"
class="section level4">
<h4>95.
<a href='https://doi.org/10.1055/S-0032-1331459' title='Open publication'>Gallo
2012: <i>Long-Gap Esophageal Atresia: a Meta-Analysis of Jejunal
Interposition, Colon Interposition, and Gastric Pull-Up</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='96'></a></p>
</div>
<div
id="gosemann-2013-open-versus-transanal-pull-through-for-hirschsprung-disease-a-systematic-review-of-long-term-outcome"
class="section level4">
<h4>96.
<a href='https://doi.org/10.1055/s-0033-1343085 ' title='Open publication'>Gosemann
2013: <i>Open Versus Transanal Pull-Through for Hirschsprung Disease: A
Systematic Review of Long-Term Outcome</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='97'></a></p>
</div>
<div
id="graziano-2015-asymptomatic-malrotation-diagnosis-and-surgical-management"
class="section level4">
<h4>97.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.06.019' title='Open publication'>Graziano
2015: <i>Asymptomatic malrotation: Diagnosis and surgical
management</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='98'></a></p>
</div>
<div
id="guo-2011-laparoscopic-versus-open-orchiopexy-for-non-palpable-undescended-testes-in-children-a-systemic-review-and-meta-analysis"
class="section level4">
<h4>98.
<a href='https://doi.org/10.1007/S00383-011-2889-1' title='Open publication'>Guo
2011: <i>Laparoscopic versus open orchiopexy for non-palpable
undescended testes in children: a systemic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><a name='99'></a></p>
</div>
<div
id="hall-2011-is-interval-appendicectomy-justified-after-successful-nonoperative-treatment-of-an-appendix-mass-in-children-a-systematic-review"
class="section level4">
<h4>99.
<a href='https://doi.org/10.1016/J.JPEDSURG.2011.01.019' title='Open publication'>Hall
2011: <i>Is interval appendicectomy justified after successful
nonoperative treatment of an appendix mass in children? A systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='100'></a></p>
</div>
<div
id="healy-2015-systematic-review-and-meta-analysis-on-the-influence-of-surgeon-specialization-on-outcomes-following-appendicectomy-in-children"
class="section level4">
<h4>100.
<a href='https://doi.org/10.1097/MD.0000000000001352' title='Open publication'>Healy
2015: <i>Systematic Review and Meta-Analysis on the Influence of Surgeon
Specialization on Outcomes Following Appendicectomy in
Children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='101'></a></p>
</div>
<div
id="healy-2016-pediatric-incidental-appendectomy-a-systematic-review"
class="section level4">
<h4>101.
<a href='https://doi.org/10.1007/s00383-015-3839-0' title='Open publication'>Healy
2016: <i>Pediatric incidental appendectomy: a systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='102'></a></p>
</div>
<div id="heloury-2012-minimally-invasive-adrenalectomy-in-children"
class="section level4">
<h4>102.
<a href='https://doi.org/10.1016/J.JPEDSURG.2011.08.003' title='Open publication'>Heloury
2012: <i>Minimally invasive adrenalectomy in children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='103'></a></p>
</div>
<div
id="huang-2015-an-updated-meta-analysis-of-laparoscopic-versus-open-pyeloplasty-for-ureteropelvic-junction-obstruction-in-children."
class="section level4">
<h4>103.
<a href='https://doi.org/pmid:26131065' title='Open publication'>Huang
2015: <i>An updated meta-analysis of laparoscopic versus open
pyeloplasty for ureteropelvic junction obstruction in
children.</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='104'></a></p>
</div>
<div
id="ishii-2014-flexible-ureteroscopy-and-lasertripsy-fursl-for-paediatric-renal-calculi-results-from-a-systematic-review"
class="section level4">
<h4>104.
<a href='https://doi.org/10.1016/J.JPUROL.2014.08.003' title='Open publication'>Ishii
2014: <i>Flexible ureteroscopy and lasertripsy (FURSL) for paediatric
renal calculi: Results from a systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='105'></a></p>
</div>
<div
id="ishii-2015-ureteroscopy-for-stone-disease-in-the-paediatric-population-a-systematic-review"
class="section level4">
<h4>105.
<a href='https://doi.org/10.1111/BJU.12927' title='Open publication'>Ishii
2015: <i>Ureteroscopy for stone disease in the paediatric population: a
systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='106'></a></p>
</div>
<div
id="ito-2014-does-frenotomy-improve-breast-feeding-difficulties-in-infants-with-ankyloglossia"
class="section level4">
<h4>106.
<a href='https://doi.org/10.1111/PED.12429' title='Open publication'>Ito
2014: <i>Does frenotomy improve breast-feeding difficulties in infants
with ankyloglossia?</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='107'></a></p>
</div>
<div
id="jia-2011-open-versus-laparoscopic-pyloromyotomy-for-pyloric-stenosis-a-meta-analysis-of-randomized-controlled-trials"
class="section level4">
<h4>107.
<a href='https://doi.org/10.1055/S-0030-1261926' title='Open publication'>Jia
2011: <i>Open versus Laparoscopic Pyloromyotomy for Pyloric Stenosis: A
Meta-analysis of Randomized Controlled Trials</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><a name='108'></a></p>
</div>
<div
id="kapralik-2016-surgical-versus-conservative-management-of-congenital-pulmonary-airway-malformation-in-children-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>108.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.11.022' title='Open publication'>Kapralik
2016: <i>Surgical versus conservative management of congenital pulmonary
airway malformation in children: A systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='109'></a></p>
</div>
<div
id="kunz-2013-primary-fascial-closure-versus-staged-closure-with-silo-in-patients-with-gastroschisis-a-meta-analysis"
class="section level4">
<h4>109.
<a href='https://doi.org/10.1016/J.JPEDSURG.2013.01.020' title='Open publication'>Kunz
2013: <i>Primary fascial closure versus staged closure with silo in
patients with gastroschisis: A meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='110'></a></p>
</div>
<div
id="landisch-2015-observation-versus-prophylactic-ladd-procedure-for-asymptomatic-intestinal-rotational-abnormalities-in-heterotaxy-syndrome-a-systematic-review"
class="section level4">
<h4>110.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.08.002' title='Open publication'>Landisch
2015: <i>Observation versus prophylactic Ladd procedure for asymptomatic
intestinal rotational abnormalities in heterotaxy syndrome: A systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='111'></a></p>
</div>
<div
id="lane-2010-paediatric-sutureless-circumcision-a-systematic-literature-review"
class="section level4">
<h4>111.
<a href='https://doi.org/10.1007/S00383-009-2475-Y' title='Open publication'>Lane
2010: <i>Paediatric sutureless circumcision: a systematic literature
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='112'></a></p>
</div>
<div
id="lansdale-2010-neonatal-endosurgical-congenital-diaphragmatic-hernia-repair"
class="section level4">
<h4>112.
<a href='https://doi.org/10.1097/SLA.0B013E3181DCA0E8' title='Open publication'>Lansdale
2010: <i>Neonatal Endosurgical Congenital Diaphragmatic Hernia
Repair</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='113'></a></p>
</div>
<div
id="lee-2010-antibiotics-and-appendicitis-in-the-pediatric-population-an-american-pediatric-surgical-association-outcomes-and-clinical-trials-committee-systematic-review"
class="section level4">
<h4>113.
<a href='https://doi.org/10.1016/J.JPEDSURG.2010.06.038' title='Open publication'>Lee
2010: <i>Antibiotics and appendicitis in the pediatric population: an
American Pediatric Surgical Association Outcomes and Clinical Trials
Committee Systematic Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='114'></a></p>
</div>
<div id="leevan-2016-management-of-pediatric-blunt-renal-trauma"
class="section level4">
<h4>114.
<a href='https://doi.org/10.1097/TA.0000000000000950' title='Open publication'>LeeVan
2016: <i>Management of pediatric blunt renal trauma</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='115'></a></p>
</div>
<div
id="liang-2011-lymphatic-sparing-versus-lymphatic-non-sparing-laparoscopic-varicocelectomy-in-children-and-adolescents-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>115.
<a href='https://doi.org/10.1055/S-0031-1271733' title='Open publication'>Liang
2011: <i>Lymphatic Sparing Versus Lymphatic Non-Sparing Laparoscopic
Varicocelectomy in Children and Adolescents: A Systematic Review and
Meta-Analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='116'></a></p>
</div>
<div
id="lishuang-2015-laparoscopic-portoenterostomy-versus-open-portoenterostomy-for-the-treatment-of-biliary-atresia-a-systematic-review-and-meta-analysis-of-comparative-studies"
class="section level4">
<h4>116.
<a href='https://doi.org/10.1007/S00383-015-3662-7' title='Open publication'>Lishuang
2015: <i>Laparoscopic portoenterostomy versus open portoenterostomy for
the treatment of biliary atresia: a systematic review and meta-analysis
of comparative studies</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='117'></a></p>
</div>
<div
id="livingston-2015-fundoplication-and-gastrostomy-versus-percutaneous-gastrojejunostomy-for-gastroesophageal-reflux-in-children-with-neurologic-impairment-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>117.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.02.020' title='Open publication'>Livingston
2015: <i>Fundoplication and gastrostomy versus percutaneous
gastrojejunostomy for gastroesophageal reflux in children with
neurologic impairment: A systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='118'></a></p>
</div>
<div
id="mauritz-2013-complete-versus-partial-fundoplication-in-children-with-gastroesophageal-reflux-disease-results-of-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>118.
<a href='https://doi.org/10.1007/S11605-013-2305-3' title='Open publication'>Mauritz
2013: <i>Complete Versus Partial Fundoplication in Children with
Gastroesophageal Reflux Disease: Results of a Systematic Review and
Meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='119'></a></p>
</div>
<div
id="mauritz-2011-the-effects-and-efficacy-of-antireflux-surgery-in-children-with-gastroesophageal-reflux-disease-a-systematic-review"
class="section level4">
<h4>119.
<a href='https://doi.org/10.1007/S11605-011-1644-1' title='Open publication'>Mauritz
2011: <i>The Effects and Efficacy of Antireflux Surgery in Children with
Gastroesophageal Reflux Disease: A Systematic Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='120'></a></p>
</div>
<div
id="mei-2011-laparoscopic-versus-open-pyeloplasty-for-ureteropelvic-junction-obstruction-in-children-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>120.
<a href='https://doi.org/10.1089/END.2010.0544' title='Open publication'>Mei
2011: <i>Laparoscopic Versus Open Pyeloplasty for Ureteropelvic Junction
Obstruction in Children: A Systematic Review and
Meta-Analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='121'></a></p>
</div>
<div
id="mullassery-2014-does-aggressive-surgical-resection-improve-survival-in-advanced-stage-3-and-4-neuroblastoma-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>121.
<a href='https://doi.org/10.3109/08880018.2014.947009' title='Open publication'>Mullassery
2014: <i>Does Aggressive Surgical Resection Improve Survival in Advanced
Stage 3 and 4 Neuroblastoma? A Systematic Review and
Meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='122'></a></p>
</div>
<div id="nagler-2011-interventions-for-primary-vesicoureteric-reflux"
class="section level4">
<h4>122.
<a href='https://doi.org/10.1002/14651858.CD001532.pub4' title='Open publication'>Nagler
2011: <i>Interventions for primary vesicoureteric reflux</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='123'></a></p>
</div>
<div
id="narayanan-2013-hepaticoduodenostomy-versus-hepaticojejunostomy-after-resection-of-choledochal-cyst-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>123.
<a href='https://doi.org/10.1016/J.JPEDSURG.2013.07.020' title='Open publication'>Narayanan
2013: <i>Hepaticoduodenostomy versus hepaticojejunostomy after resection
of choledochal cyst: A systematic review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='124'></a></p>
</div>
<div
id="nasr-2010-comparison-of-the-nuss-and-the-ravitch-procedure-for-pectus-excavatum-repair-a-meta-analysis"
class="section level4">
<h4>124.
<a href='https://doi.org/10.1016/J.JPEDSURG.2010.02.012' title='Open publication'>Nasr
2010: <i>Comparison of the Nuss and the Ravitch procedure for pectus
excavatum repair: a meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='125'></a></p>
</div>
<div
id="nasr-2013-mechanical-traction-techniques-for-long-gap-esophageal-atresia-a-critical-appraisal"
class="section level4">
<h4>125.
<a href='https://doi.org/10.1055/S-0033-1347916' title='Open publication'>Nasr
2013: <i>Mechanical Traction Techniques for Long-Gap Esophageal Atresia:
A Critical Appraisal</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='126'></a></p>
</div>
<div
id="nataraja-2013-the-incidence-of-intraabdominal-abscess-formation-following-laparoscopic-appendicectomy-in-children-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>126.
<a href='https://doi.org/10.1089/lap.2012.0522 ' title='Open publication'>Nataraja
2013: <i>The Incidence of Intraabdominal Abscess Formation Following
Laparoscopic Appendicectomy in Children: A Systematic Review and
Meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='127'></a></p>
</div>
<div
id="nicolau-2011-is-laparoscopy-still-needed-in-blunt-abdominal-trauma"
class="section level4">
<h4>127.
<a href='https://doi.org/pmid:21520776' title='Open publication'>Nicolau
2011: <i>Is laparoscopy still needed in blunt abdominal
trauma</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='128'></a></p>
</div>
<div
id="oliveira-2016-neophalloplasty-in-boys-with-aphallia-a-systematic-review"
class="section level4">
<h4>128.
<a href='https://doi.org/10.1016/J.JPUROL.2015.10.003' title='Open publication'>Oliveira
2016: <i>Neophalloplasty in boys with aphallia: A systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='129'></a></p>
</div>
<div
id="oomen-2012-open-versus-laparoscopic-pyloromyotomy-for-hypertrophic-pyloric-stenosis-a-systematic-review-and-meta-analysis-focusing-on-major-complications"
class="section level4">
<h4>129.
<a href='https://doi.org/10.1007/S00464-012-2174-Y' title='Open publication'>Oomen
2012: <i>Open Versus Laparoscopic Pyloromyotomy for Hypertrophic Pyloric
Stenosis: A Systematic Review and Meta-Analysis Focusing on Major
Complications</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='130'></a></p>
</div>
<div
id="parolini-2016-the-management-of-newborns-with-esophageal-atresia-and-right-aortic-arch-a-systematic-review-or-still-unsolved-problem"
class="section level4">
<h4>130.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.10.043' title='Open publication'>Parolini
2016: <i>The management of newborns with esophageal atresia and right
aortic arch: A systematic review or still unsolved problem</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='131'></a></p>
</div>
<div
id="parolini-2014-cervicalthoracotomicthoracoscopic-approaches-for-h-type-congenital-tracheo-esophageal-fistula-a-systematic-review"
class="section level4">
<h4>131.
<a href='https://doi.org/10.1016/J.IJPORL.2014.04.011' title='Open publication'>Parolini
2014: <i>Cervical/thoracotomic/thoracoscopic approaches for H-type
congenital tracheo-esophageal fistula: A systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='132'></a></p>
</div>
<div
id="peters-2013-morbidity-and-mortality-in-total-esophagogastric-dissociation-a-systematic-review"
class="section level4">
<h4>132.
<a href='https://doi.org/10.1016/J.JPEDSURG.2012.11.049' title='Open publication'>Peters
2013: <i>Morbidity and mortality in total esophagogastric dissociation:
A systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='133'></a></p>
</div>
<div
id="peycelon-2014-minimally-invasive-surgery-in-childhood-cancer-a-challenging-future"
class="section level4">
<h4>133.
<a href='https://doi.org/10.1055/S-0034-1396419' title='Open publication'>Peycelon
2014: <i>Minimally Invasive Surgery in Childhood Cancer: A Challenging
Future</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='134'></a></p>
</div>
<div
id="pfistermuller-2015-meta-analysis-of-complication-rates-of-the-tubularized-incised-plate-tip-repair"
class="section level4">
<h4>134.
<a href='https://doi.org/10.1016/J.JPUROL.2014.12.006' title='Open publication'>Pfistermuller
2015: <i>Meta-analysis of complication rates of the tubularized incised
plate (TIP) repair</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='135'></a></p>
</div>
<div
id="puligandla-2015-management-of-congenital-diaphragmatic-hernia-a-systematic-review-from-the-apsa-outcomes-and-evidence-based-practice-committee"
class="section level4">
<h4>135.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.09.010' title='Open publication'>Puligandla
2015: <i>Management of congenital diaphragmatic hernia: A systematic
review from the APSA outcomes and evidence based practice
committee</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='136'></a></p>
</div>
<div
id="reddy-2010-ureteroscopy-the-standard-of-care-in-the-management-of-upper-tract-urolithiasis-in-children"
class="section level4">
<h4>136.
<a href='https://doi.org/10.4103/0970-1591.74459' title='Open publication'>Reddy
2010: <i>Ureteroscopy: The standard of care in the management of upper
tract urolithiasis in children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='137'></a></p>
</div>
<div
id="romao-2012-what-is-the-best-prosthetic-material-for-patch-repair-of-congenital-diaphragmatic-hernia-comparison-and-meta-analysis-of-porcine-small-intestinal-submucosa-and-polytetrafluoroethylene"
class="section level4">
<h4>137.
<a href='https://doi.org/10.1016/J.JPEDSURG.2012.01.009' title='Open publication'>Romao
2012: <i>What is the best prosthetic material for patch repair of
congenital diaphragmatic hernia? Comparison and meta-analysis of porcine
small intestinal submucosa and polytetrafluoroethylene</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='138'></a></p>
</div>
<div
id="ross-2015-the-role-of-preformed-silos-in-the-management-of-infants-with-gastroschisis-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>138.
<a href='https://doi.org/10.1007/S00383-015-3691-2' title='Open publication'>Ross
2015: <i>The role of preformed silos in the management of infants with
gastroschisis: a systematic review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='139'></a></p>
</div>
<div
id="ruttenstock-2010-systematic-review-and-meta-analysis-of-enterocolitis-after-one-stage-transanal-pull-through-procedure-for-hirschsprungs-disease"
class="section level4">
<h4>139.
<a href='https://doi.org/10.1007/S00383-010-2695-1' title='Open publication'>Ruttenstock
2010: <i>Systematic review and meta-analysis of enterocolitis after
one-stage transanal pull-through procedure for Hirschsprungs
disease</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='140'></a></p>
</div>
<div
id="rynja-2011-functional-cosmetic-and-psychosexual-results-in-adult-men-who-underwent-hypospadias-correction-in-childhood"
class="section level4">
<h4>140.
<a href='https://doi.org/10.1016/J.JPUROL.2011.02.008' title='Open publication'>Rynja
2011: <i>Functional, cosmetic and psychosexual results in adult men who
underwent hypospadias correction in childhood</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='141'></a></p>
</div>
<div
id="saldaa-2013-single-incision-pediatric-endosurgery-a-systematic-review"
class="section level4">
<h4>141.
<a href='https://doi.org/10.1089/lap.2012.0467' title='Open publication'>Saldaa
2013: <i>Single-Incision Pediatric Endosurgery: A Systematic
Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='142'></a></p>
</div>
<div
id="sauerland-2010-laparoscopic-versus-open-surgery-for-suspected-appendicitis"
class="section level4">
<h4>142.
<a href='https://doi.org/10.1002/14651858.CD001546.PUB3' title='Open publication'>Sauerland
2010: <i>Laparoscopic versus open surgery for suspected
appendicitis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><a name='143'></a></p>
</div>
<div
id="scholfield-2016-laparoscopic-duhamel-procedure-for-hirschsprungs-disease-systematic-review-and-meta-analysis"
class="section level4">
<h4>143.
<a href='https://doi.org/10.1089/lap.2015.0121' title='Open publication'>Scholfield
2016: <i>Laparoscopic Duhamel Procedure for Hirschsprungs Disease:
Systematic Review and Meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='144'></a></p>
</div>
<div
id="sharp-2015-treatment-of-idiopathic-achalasia-in-the-pediatric-population-a-systematic-review"
class="section level4">
<h4>144.
<a href='https://doi.org/10.1055/S-0035-1544174' title='Open publication'>Sharp
2015: <i>Treatment of Idiopathic Achalasia in the Pediatric Population:
A Systematic Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><a name='145'></a></p>
</div>
<div
id="shawyer-2014-the-management-of-postoperative-reflux-in-congenital-esophageal-atresiatracheoesophageal-fistula-a-systematic-review"
class="section level4">
<h4>145.
<a href='https://doi.org/10.1007/S00383-014-3548-0' title='Open publication'>Shawyer
2014: <i>The management of postoperative reflux in congenital esophageal
atresiatracheoesophageal fistula: a systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='146'></a></p>
</div>
<div
id="shawyer-2015-laparoscopic-versus-open-repair-of-recto-bladderneck-and-recto-prostatic-anorectal-malformations-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>146.
<a href='https://doi.org/10.1007/S00383-014-3626-3' title='Open publication'>Shawyer
2015: <i>Laparoscopic versus open repair of recto-bladderneck and
recto-prostatic anorectal malformations: a systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='147'></a></p>
</div>
<div
id="shen-2015-laparoscopic-versus-open-surgery-in-children-with-choledochal-cysts-a-meta-analysis"
class="section level4">
<h4>147.
<a href='https://doi.org/10.1007/S00383-015-3705-0' title='Open publication'>Shen
2015: <i>Laparoscopic versus open surgery in children with choledochal
cysts: a meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='148'></a></p>
</div>
<div
id="siddiqui-2011-a-meta-analysis-of-outcomes-after-open-and-laparoscopic-nissens-fundoplication-for-gastro-oesophageal-reflux-disease-in-children"
class="section level4">
<h4>148.
<a href='https://doi.org/10.1007/S00383-010-2698-Y' title='Open publication'>Siddiqui
2011: <i>A meta-analysis of outcomes after open and laparoscopic
Nissens fundoplication for gastro-oesophageal reflux disease in
children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='149'></a></p>
</div>
<div
id="siminas-2015-current-surgical-management-of-pediatric-idiopathic-constipation"
class="section level4">
<h4>149.
<a href='https://doi.org/10.1097/SLA.0000000000001191' title='Open publication'>Siminas
2015: <i>Current Surgical Management of Pediatric Idiopathic
Constipation</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='150'></a></p>
</div>
<div
id="sklar-2014-laparoscopic-versus-open-reduction-of-intussusception-in-children-a-retrospective-review-and-meta-analysis"
class="section level4">
<h4>150.
<a href='https://doi.org/10.1089/lap.2013.0415 ' title='Open publication'>Sklar
2014: <i>Laparoscopic Versus Open Reduction of Intussusception in
Children: A Retrospective Review and Meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><a name='151'></a></p>
</div>
<div
id="sola-2010-peritoneal-drainage-versus-laparotomy-for-necrotizing-enterocolitis-and-intestinal-perforation-a-meta-analysis"
class="section level4">
<h4>151.
<a href='https://doi.org/10.1016/J.JSS.2009.05.007' title='Open publication'>Sola
2010: <i>Peritoneal Drainage versus Laparotomy for Necrotizing
Enterocolitis and Intestinal Perforation: A Meta-Analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='152'></a></p>
</div>
<div
id="symeonidis-2016-laparoendoscopic-single-site-surgery-less-for-major-urological-procedures-in-the-pediatric-population-a-systematic-review"
class="section level4">
<h4>152.
<a href='https://doi.org/10.1016/J.IJSU.2016.03.040' title='Open publication'>Symeonidis
2016: <i>Laparoendoscopic single-site surgery (LESS) for major
urological procedures in the pediatric population: A systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='153'></a></p>
</div>
<div
id="tan-2016-screening-and-treatment-of-intestinal-rotational-abnormalities-in-heterotaxy-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>153.
<a href='https://doi.org/10.1016/J.JPEDS.2015.12.074' title='Open publication'>Tan
2016: <i>Screening and Treatment of Intestinal Rotational Abnormalities
in Heterotaxy: A Systematic Review and Meta-Analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='154'></a></p>
</div>
<div
id="terui-2015-surgical-approaches-for-neonatal-congenital-diaphragmatic-hernia-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>154.
<a href='https://doi.org/10.1007/S00383-015-3765-1' title='Open publication'>Terui
2015: <i>Surgical approaches for neonatal congenital diaphragmatic
hernia: a systematic review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='155'></a></p>
</div>
<div
id="thomson-2015-laparoscopic-assistance-for-primary-transanal-pull-through-in-hirschsprungs-disease-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>155.
<a href='https://doi.org/10.1136/BMJOPEN-2014-006063' title='Open publication'>Thomson
2015: <i>Laparoscopic assistance for primary transanal pull-through in
Hirschsprungs disease: a systematic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='156'></a></p>
</div>
<div
id="thyoka-2013-balloon-dilatation-of-anastomotic-strictures-secondary-to-surgical-repair-of-oesophageal-atresia-a-systematic-review"
class="section level4">
<h4>156.
<a href='https://doi.org/10.1007/S00247-013-2693-2' title='Open publication'>Thyoka
2013: <i>Balloon dilatation of anastomotic strictures secondary to
surgical repair of oesophageal atresia: a systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='157'></a></p>
</div>
<div
id="van-dalen-2015-minimally-invasive-surgery-versus-open-surgery-for-the-treatment-of-solid-abdominal-and-thoracic-neoplasms-in-children"
class="section level4">
<h4>157.
<a href='https://doi.org/10.1002/14651858.CD008403.pub3' title='Open publication'>van
Dalen 2015: <i>Minimally invasive surgery versus open surgery for the
treatment of solid abdominal and thoracic neoplasms in
children</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='158'></a></p>
</div>
<div
id="vanden-berg-2016-nephron-sparing-surgery-for-wilms-tumor-a-systematic-review"
class="section level4">
<h4>158.
<a href='https://doi.org/10.1016/J.UROLONC.2015.07.003' title='Open publication'>Vanden
Berg 2016: <i>Nephron-sparing surgery for Wilms tumor: A systematic
review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='159'></a></p>
</div>
<div
id="van-den-hondel-2014-to-split-or-not-to-split-colostomy-complications-for-anorectal-malformations-or-hirschsprung-disease-a-single-center-experience-and-a-systematic-review-of-the-literature"
class="section level4">
<h4>159.
<a href='https://doi.org/10.1055/S-0033-1351663' title='Open publication'>van
den Hondel 2014: <i>To Split or Not to Split: Colostomy Complications
for Anorectal Malformations or Hirschsprung Disease: A Single Center
Experience and a Systematic Review of the Literature</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='160'></a></p>
</div>
<div
id="vernon-roberts-2013-fundoplication-versus-postoperative-medication-for-gastro-oesophageal-reflux-in-children-with-neurological-impairment-undergoing-gastrostomy"
class="section level4">
<h4>160.
<a href='https://doi.org/10.1002/14651858.CD006151.pub3 ' title='Open publication'>Vernon-Roberts
2013: <i>Fundoplication versus postoperative medication for
gastro-oesophageal reflux in children with neurological impairment
undergoing gastrostomy</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><a name='161'></a></p>
</div>
<div
id="wang-2013-systematic-review-and-meta-analysis-of-studies-comparing-the-perimeatal-based-flap-and-tubularized-incised-plate-techniques-for-primary-hypospadias-repair"
class="section level4">
<h4>161.
<a href='https://doi.org/10.1007/S00383-013-3335-3' title='Open publication'>Wang
2013: <i>Systematic review and meta-analysis of studies comparing the
perimeatal-based flap and tubularized incised-plate techniques for
primary hypospadias repair</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='162'></a></p>
</div>
<div
id="wayne-2015-what-is-the-ideal-surgical-approach-for-intra-abdominal-testes-a-systematic-review"
class="section level4">
<h4>162.
<a href='https://doi.org/10.1007/S00383-015-3676-1' title='Open publication'>Wayne
2015: <i>What is the ideal surgical approach for intra-abdominal testes?
a systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='163'></a></p>
</div>
<div
id="weih-2012-current-practice-and-future-perspectives-in-the-treatment-of-short-bowel-syndrome-in-childrena-systematic-review"
class="section level4">
<h4>163.
<a href='https://doi.org/10.1007/S00423-011-0874-8' title='Open publication'>Weih
2012: <i>Current practice and future perspectives in the treatment of
short bowel syndrome in childrena systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='164'></a></p>
</div>
<div
id="wenk-2015-incidence-of-metachronous-contralateral-inguinal-hernias-in-children-following-unilateral-repair-a-meta-analysis-of-prospective-studies"
class="section level4">
<h4>164.
<a href='https://doi.org/10.1016/J.JPEDSURG.2015.08.056' title='Open publication'>Wenk
2015: <i>Incidence of metachronous contralateral inguinal hernias in
children following unilateral repair  A meta-analysis of prospective
studies</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
</tr>
</tbody>
</table>
<p><br><a name='165'></a></p>
</div>
<div
id="wilkinson-2012-outcomes-in-distal-hypospadias-a-systematic-review-of-the-mathieu-and-tubularized-incised-plate-repairs"
class="section level4">
<h4>165.
<a href='https://doi.org/10.1016/J.JPUROL.2010.11.008' title='Open publication'>Wilkinson
2012: <i>Outcomes in distal hypospadias: A systematic review of the
Mathieu and tubularized incised plate repairs</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='166'></a></p>
</div>
<div
id="wright-2013-effect-of-preoperative-hormonal-stimulation-on-postoperative-complication-rates-after-proximal-hypospadias-repair-a-systematic-review"
class="section level4">
<h4>166.
<a href='https://doi.org/10.1016/J.JURO.2013.02.3234' title='Open publication'>Wright
2013: <i>Effect of Preoperative Hormonal Stimulation on Postoperative
Complication Rates After Proximal Hypospadias Repair: A Systematic
Review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='167'></a></p>
</div>
<div
id="yang-2011-laparoscopic-vs-open-herniorrhaphy-in-the-management-of-pediatric-inguinal-hernia-a-systemic-review-and-meta-analysis"
class="section level4">
<h4>167.
<a href='https://doi.org/10.1016/J.JPEDSURG.2011.04.001' title='Open publication'>Yang
2011: <i>Laparoscopic vs open herniorrhaphy in the management of
pediatric inguinal hernia: a systemic review and
meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='168'></a></p>
</div>
<div
id="yang-2013-postoperative-intussusceptions-in-children-and-infants-a-systematic-review"
class="section level4">
<h4>168.
<a href='https://doi.org/10.1007/S00383-013-3345-1' title='Open publication'>Yang
2013: <i>Postoperative intussusceptions in children and infants: a
systematic review</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='169'></a></p>
</div>
<div
id="youssef-2016-flap-versus-fascial-closure-for-gastroschisis-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>169.
<a href='https://doi.org/10.1016/J.JPEDSURG.2016.02.010' title='Open publication'>Youssef
2016: <i>Flap versus fascial closure for gastroschisis: a systematic
review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='170'></a></p>
</div>
<div
id="zani-2015-is-single-incision-pediatric-endoscopic-surgery-more-painful-than-standard-laparoscopy-in-children-personal-experience-and-review-of-the-literature."
class="section level4">
<h4>170.
<a href='https://doi.org/pmid:25034218' title='Open publication'>Zani
2015: <i>Is single incision pediatric endoscopic surgery more painful
than standard laparoscopy in children? Personal experience and review of
the literature.</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='171'></a></p>
</div>
<div
id="zhao-2015-single-incision-versus-conventional-laparoscopic-appendicectomy-in-children-a-systematic-review-and-meta-analysis"
class="section level4">
<h4>171.
<a href='https://doi.org/10.1007/S00383-015-3680-5' title='Open publication'>Zhao
2015: <i>Single-incision versus conventional laparoscopic appendicectomy
in children: a systematic review and meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><a name='172'></a></p>
</div>
<div
id="zhu-2016-minimally-invasive-surgery-for-congenital-diaphragmatic-hernia-a-meta-analysis"
class="section level4">
<h4>172.
<a href='https://doi.org/10.1007/S10029-015-1423-0' title='Open publication'>Zhu
2016: <i>Minimally invasive surgery for congenital diaphragmatic hernia:
a meta-analysis</i></a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Title: Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Abstract / Structured summary: Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Rationale: Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Introduction / Objectives: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Protocol and registration: Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Eligibility criteria: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Information sources: Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Search: Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Study selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data collection process: Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Data items: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias in individual studies: Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Summary measures: State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Synthesis of results: Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Risk of bias across studies: Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Methods / Additional analyses: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study selection: Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Study characteristics: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias within studies: Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Results of individual studies: For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Synthesis of results: Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Risk of bias across studies: Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Results / Additional analysis: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Summary of evidence: Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Limitations: Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Discussion / Conclusions: Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Funding: Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a yes.">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the others work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select yes (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for grey literature or unpublished literature, indicate yes. SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select no.">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul Follow-up poorly reported in general">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (low or high is fine, as long as it is clear which studies scored low and which scored high; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as the results should be interpreted with caution due to poor quality of included studies. Cannot score yes for this question if scored no for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate yes if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score no. Score yes if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a yes, must indicate source of funding or support for the systematic review AND for each of the included studies.">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLMs combined (consistent in 5/9)
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
def.
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br></p>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
</div>
</div>
</div>

</div>

<script>
$(document).ready(function() {
  // add bootstrap table styles to pandoc tables
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed table-sm');

  // initialize mathjax

});
</script>

<script type="text/javascript">
$(document).ready(function () {
  FlexDashboard.init({
    fillPage: true,
    orientation: "columns",
    storyboard: false,
    defaultFigWidth: 576,
    defaultFigHeight: 460,
    defaultFigWidthMobile: 360,
    defaultFigHeightMobile: 460,
    resize_reload: true
  });
  var navbar = $(".navbar").first();
  var body = $("body").first();
  var sidebar = $(".section.sidebar").first();
  function addNavbarPadding() {
    var navHeight = navbar.outerHeight();
    body.css("padding-top", (navHeight + 8) + "px");
    sidebar.css("top", navHeight + "px");
    var resizeEvent = window.document.createEvent("UIEvents");
    resizeEvent.initUIEvent("resize", true, false, window, 0);
    window.dispatchEvent(resizeEvent);
  }
  if (!window.Shiny) setTimeout(addNavbarPadding, 100);
  $(document).on("shiny:idle", function() {
    setTimeout(addNavbarPadding, 50);
  });
});
</script>

</body>
</html>
